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INTEGRATED ANALYSIS OF MIRNA/MRNA EXPRESSION AND GENE METHYLATION USING 
SPARSE CANONICAL CORRELATION ANALYSIS 
Dake Yang 
April 1st, 2016 
MicroRNAs (miRNAs) are a large number of small endogenous non-coding RNA molecules (18-25 
nucleotides in length) which regulate expression of genes post-transcriptionally. While a variety of 
algorithms exist for determining the targets of miRNAs, they are generally based on sequence information 
and frequently produce lists consisting of thousands of genes. Canonical correlation analysis (CCA) is a 
multivariate statistical method that can be used to find linear relationships between two data sets, and here 
we apply CCA to find the linear combination of differentially expressed miRNAs and their corresponding 
target genes having maximal negative correlation.  Due to the high dimensionality, sparse CCA is used to 
constrain the problem and obtain a solution. A novel gene set enrichment analysis statistic is proposed based 
on the sparse CCA results for estimating the significance of predefined gene sets. The methods are illustrated 
with both a simulation study and real miRNA-mRNA expression data. 
DNA methylation is a process of adding a methyl group to DNA by a group of enzymes collectively known 
as DNA methyltransferases which is an epigenetic modification critical to normal genome regulation and 
development. In order to understand the role of DNA methylation in gene differentiation, we analyze 
genome-scale DNA methylation patterns and gene expression data using sparse CCA to find linear 
combinations between the two data sets which have maximal negative correlation. In a similar spirit to the 
miRNA-mRNA study, we create a GSEA statistic with weight vectors from the sparse CCA method and 
assess the significance of predefined gene sets. The method is exemplified with real gene expression / DNA 
methylation data regarding the development of the embryonic murine palate. 
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MicroRNAs (miRNAs) are a large number of small endogenous non-coding RNA molecules (18-25 
nucleotides in length) processed from 70–100 nucleotide hairpin pre-miRNAs. The miRNAs are transcribed 
by RNA polymerase II from independent genes or represent introns of messenger RNA transcripts. The 
miRNAs have been discovered and found to execute key functions in a ribonucleoprotein complex called 
RNA-induced silencing complex (RISC) and guide the RISC to the target mRNA in both plant and animal 
systems (Nelson and Weiss, 2008). The miRNAs bind to their target mRNA 5’UTR and can down regulate 
gene expression through directly inhibiting their translation and/or resulting in the destabilization of their 
target mRNAs at the posttranscriptional level. Currently, thousands of these small regulators have been 
identified in various species. It is believed that each miRNA potentially targets between 100 and 200 mRNAs, 
and miRNAs regulate between 20%- 30% of all human genes (Flynt and Lai, 2008; Nilsen, 2007). So, the 
potential relationships between miRNAs and mRNAs are extremely complex. Therefore, miRNAs play a 
major role in multiple essential biological processes including development, differentiation, apoptosis and 
cellular proliferation. There is also strong evidence that miRNAs are involved in pathological processes and 
contribute to the occurrence and development of some cancers. Specifically, abnormally expressed miRNAs 
have been shown to be crucial contributors and may serve as biomarkers in many human diseases, as found 
by comparing distinct miRNA expression for human cancers with their normal counterparts.  
The development of microarray technology has equipped scientific researchers with the ability to 
simultaneously study, in a single experiment, the expression patterns of thousands of genes within the cells 
of a biological sample. This technology has been successfully extended to the arena of miRNAs to generate 
“microRNA gene expression profiles" of the cell cycle (Corney, et al., 2007), cell differentiation (Zhan, et 
al., 2007), cell death (Kren, et al., 2009), embryonic development, stem cell differentiation (Lakshmipathy, 
et al., 2007), different types of cancers (Gottardo, et al., 2007), the diseased heart (Tatsuguchi, et al., 2007) 
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and normal as well as diseased neural tissue (Ferretti, et al., 2009). The typical first step in determining the 
important miRNAs for regulation of gene expression is identifying differentially expressed miRNAs. That 
is, miRNAs that are differentially expressed between normal and diseased tissue types, or exhibit changes in 
expression over time. Then, these miRNAs are evaluated to determine which biochemical and molecular 
systems they target. Of critical importance is to discover how the miRNAs are targeting the biological 
pathways, i.e. what specific genes/transcripts (within those pathways) are being regulated by the differentially 
expressed miRNAs. Identifying the putative target transcripts based on sequence complementarity between 
the 3’-UTR of the mRNAs and the ‘seed region’ of the miRNA (nucleotides 2–7) is an important step. There 
are several databases which include lists of miRNA targets which are computationally predicted, including 
miRBase (Kozomara and Griffiths-Jones, 2014), miRanda (John, et al., 2004) and TargetScan (Lewis, et al., 
2003). However, the issue is that computational methods predict hundreds to thousands of target mRNAs for 
each miRNA. Furthermore, the information concerning which of the potential miRNA targets are regulated 
during the biological process of interest is not included. To help solve this problem, we can identify the 
predicted target mRNAs which are inversely correlated with miRNA expression values as the potential 
mRNA-miRNA associations. The motivation behind this approach is that the main regulatory mechanism of 
miRNAs is to bind complementary regions within the 3'-untranslated region of mRNA transcripts which 
results in degradation of the mRNA target transcript. So, a more definitive determination of miRNA-mRNA 
interactions involves integrated analysis from both miRNA and mRNA expression values. These potential 
targets can then be further analyzed for enrichment in certain biological functions or pathways. 
Regulation of gene expression by miRNA binding of mRNA transcripts can be considered one mode of 
epigenetic regulation. Another mode of epigenetic regulation is DNA methylation of cytosine nucleotides, 
which is an epigenetic mechanism that occurs throughout the human genome. This covalent modification is 
a genomic DNA mark that commonly happens at a 5-carbon position of cytosine, generally within a 5’-CpG-
3’ dinucleotide. Approximately 1.5% of human genomic DNA contains this dinucleotide (Lister, et al., 2009) 
which usually forms as clusters of un-methylated cytosine guanosine dinucleotides (CpGs) called CpG 
islands. These islands are generally present in gene promoter regions and do not methylate. DNA methylation 
occurs at the 5' carbon of the cytosine ring by adding a methyl group (Bird, 2002) and forming 5-
methylcytosine. These methyl groups modify the function of DNA and effectively suppress transcription.  
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In general, DNA methylation effects biological processes in two ways. First, DNA methylation can steadily 
change the expression of genes in cells from embryonic cell division and differentiation of stem cells into a 
particular organization. The resulting change is usually one-way and permanent, stopping a cell from turning 
back into a stem cell or converted into different cell types. Second, via deleting hydroxyl methyl groups 
rather than completely removing methyl groups by dilution as cells divide or in a faster active process, DNA 
methylation can be passively deleted (Wossidlo, et al., 2011). DNA methylation is usually deleted and re-
established through continuous cell division in the process of development. 
DNA methylation at the 5’ position of cytosine has been found in each examined vertebrate and generally, 
reduces gene expression with a specific effect. It usually occurs in the CpG dinucleotide context in adult 
somatic cells. However, non- CpG methylation is common in embryonic stem cells (Haines, et al., 2001) and 
also plays a role in neural development (Lister, et al., 2013). In mammalian DNA, 60%- 90% of CpGs are 
methylated, and 5-methylcytosine is primarily found in CpGs (Tucker, 2001). These CpGs play a key role in 
maintenance of cellular functions and the regulation of gene expression (Jones and Takai, 2001). In the 
human genome, these CpG sites exist in less than expected frequencies for the majority of the genome but 
are found more frequently among CpG islands. These CpG islands are generally found in or near promoter 
regions of genes (Herman and Baylin, 2003) and act as potential regulators of gene expression. In the 
promoter region, hypermethylation usually occurs in the CpG island area and is related to gene inactivation. 
Recently, a genome-wide high-resolution DNA methylation analysis of a primary human fibroblast cell line 
demonstrated that in genomic DNA, 4.25% of total cytosines are methylated, 67.7% of CpGs are methylated, 
and 99.98% of DNA methylation occurs in CpG dinucleotides (Lister, et al., 2009). In many disease processes, 
such as cancer (Baylin, 2005), gene promoter CpG islands have abnormal hypermethylation, causing 
transcriptional silencing which can be inherited in the daughter cells after cell division. These changes in 
DNA methylation are considered to be an important part of the development of cancer. Hypomethylation 
generally appears with chromosome instability and loss of imprinting; on the other hand hypermethylation is 
linked with the promoter methylation and possible secondary gene silencing (cancer suppressor genes), but 
may be an epigenetic therapy target. DNA methylation is essential during embryonic development, and DNA 
methylation patterns usually keep high fidelity to the daughter cells. Hypermethylation and hypomethylation 
have been associated with a large number of human malignant tumors compared to normal tissue. Generally 
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speaking, for carcinogenic methylation changes there is an increase in DNA methylation associated tumor 
suppressor genes and a decrease related to oncogenes (Gonzalo, 2010). 
Many studies have explored the association of gene expression and DNA methylation, but only a few reported 
the combination of two features using a gene set enrichment analysis to enhance biological pathway analysis. 
In our research, we develop a statistic to combine gene expression and DNA methylation and performed a 
gene set enrichment analysis to detect relevant pathways to the phenotype of interest. The purpose of the 
integration of two features is to increase the power of detecting significant pathways related to the gene 
expression. 
In this dissertation, we develop methods for integrating miRNA and mRNA expression data, as well as 
mRNA expression and DNA methylation data, based on sparse canonical correlation analysis (SCCA). This 
approach has an advantage relative to pairwise comparisons by reducing the dimension of the data to 
potentially increase both statistical power using this data and biological interpretability. Further, we develop 
a novel gene set enrichment analysis (GSEA) approach based on the integrated analysis using SCCA. GSEA 
allows for testing the potential enrichment of pathways and biological terms of genes that are significantly 
associated with the phenotype of interest. The rest of this dissertation is organized as follows. In Chapter 2, 
we develop an approach for integrated analysis of miRNA and mRNA expression data using SCCA and 
motivate the derivation of our novel test statistic for GSEA based on this analysis. In Chapter 3, we evaluate 
our SCCA-GSEA statistic for miRNA / mRNA expression data using simulated data, and compare it with a 
similar statistic based on pairwise correlation analysis of miRNA / mRNA data. In Chapter 4 we evaluate the 
same SCCA-GSEA statistic for detecting GO terms and KEGG pathways using several real data sets of 
miRNA / mRNA expression data in cancer vs. normal tissue and in tissue related to embryonic development 
of the murine neural tube. In Chapter 5, we develop an analog of the SCCA-GSEA statistic for use with 
integrated analysis of mRNA expression and DNA methylation data. In Chapter 6 we evaluate this statistic 
for detecting regions of epigenetic regulation associated with GO terms in data relating to murine embryonic 





CHAPTER II  
METHOD OF INTEGRATED ANALYSIS OF MIRNA AND MRNA EXPRESSION 
2.1. Sparse canonical correlation analysis 
In this research we focus on identifying the predicted target genes which have maximum negative correlation 
with miRNAs of interest, e.g. miRNAs that are down- or up-regulated between two sets of biological samples. 
So, the objective is to find an analytic method which establishes the relationships between sets of 
measurements from the same group of subjects and further reduces the dimensionality of the data. An often 
used method is principal component analysis (PCA). PCA is used for reducing the dimensions of the data 
sets, modeling the potential structure in the data and then aggregating the original variables into composite 
latent variables. As a final step, PCA is often used to model the relationships between the latent variables and 
additional outcome variables, an approach called principal components regression (PCR). But, there are two 
main disadvantages of this approach. One is that in our research we want to measure the correlation between 
two or among more sets of variables from populations, but PCA is mainly to maximize the variance within 
only one set of variables by creating composite measures. Another disadvantage is that with large scale data 
sets, these composite measures are based on thousands of variables. Since PCA creates latent variables 
(principal components) which are linear combinations of the entire sets of variables, the resulting components 
may lack interpretability and be difficult to visualize. The first disadvantage can be solved using the canonical 
correlation analysis (CCA) method. CCA is a classical technique due to Hotelling (1936) that identifies 
relationships among sets of variables on the same set of subjects. Specifically, CCA seeks linear combinations 
of the variables in two populations which have maximal correlation. Suppose there are two data  𝑿1 and 
𝑿2with the same number of observations n. The first data matrix 𝑿1is a 𝑛 × 𝑝1 matrix corresponding to 𝑝1  
variables with 𝑛 observations and the second matrix 𝑿2 is a 𝑛 × 𝑝2 matrix corresponding to 𝑝2  variables on 
the same set of observations. We assume that all columns of the matrices are standardized. The objective of 
CCA is to identify linear combinations of variables in 𝑿1 and 𝑿2 which have maximum positive correlation.
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𝑇𝑿2. Then, we define 
the linear combinations of 𝑿1 and 𝑿2 as 𝑼 =  𝑿1𝒖 and 𝑽 =  𝑿2𝒗, where vectors 𝒖 ∈  ℝ
𝑝1  and 𝒗 ∈  ℝ𝑝2 are 
the weights used to determine the linear combination of measurements in 𝑿1 and 𝑿2 which are maximally 
correlated with each other. The linear combinations 𝑼 =  𝑿1𝒖  and 𝑽 =  𝑿2𝒗  are termed the sample 
canonical variables. So, CCA aims to find 𝒖 and 𝒗 in order to maximize 𝒖𝑇𝑿1




𝑇𝑿2𝒗 = 1.  
The traditional CCA (Hotelling, 1936) approach fits the linear combinations or canonical vectors by including 
all variables from both data sets. In our research, the number of genomic regions / features of interest under 
consideration often reaches tens of thousands, while the number of samples is typically limited (in the tens 
to hundreds). In this case, linear combinations of the whole set of features lack biological interpretability 
because there are too many variables under consideration. Furthermore, insufficient sample size and high 
dimensional data result in inaccurately estimated parameters and many computational problems 
(Parkhomenko, et al., 2009).  
Sparse CCA (SCCA) is an extension to classical CCA which solves the aforementioned problems concerning 
high dimensional data, and aids in biological interpretability by identifying sparse groups of associated 
variables. Instead of including all the variables in both data sets for finding correlation between two sets of 
variables as with traditional CCA, SCCA uses a penalty term to reduce the dimensionality of the problem. 
Thus, the results of SCCA are expected to be more robust compared to CCA in the high dimensional setting. 
The SCCA method introduced by (Witten and Tibshirani, 2009) maximized 𝒖𝑇𝑿1
𝑇𝑿2𝒗 subject to constraints 





subject to ‖𝒖‖2  ≤ 1, ‖𝒗‖2  ≤ 1, 𝑃1(𝒖) ≤  𝑐1, 𝑃2(𝒗) ≤  𝑐2  
Here, the penalty functions 𝑃1 and 𝑃2 are either lasso (with 𝑃1(𝒖) =  ‖𝒖‖1) or fused lasso (with 𝑃1(𝒖) =
 ∑ |𝒖𝑗| + 𝑗 ∑ |𝒖𝑗 − 𝒖(𝑗−1)|𝑗  ) penalties. The lasso penalty results in sparse 𝒖  and/or 𝒗  for appropriately 
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chosen 𝑐1  and 𝑐2  (where 1 ≤  𝑐1 ≤  √𝑝1  and 1 ≤  𝑐2 ≤  √𝑝2), while the fused lasso penalty results in 𝑢 
and/or 𝑣 which are both sparse and smooth. Witten and Tibshirani (2009) introduce algorithms for estimating 
unconstrained 𝑢 and 𝑣 and for when 𝑢 and 𝑣 are constrained to be non-negative (or non-positive).    
Witten and Tibshirani (2009) also introduced the concept of sparse multiple CCA (sparse mCCA) which 
generalizes sparse CCA to the setting of multiple data sets 𝑿1 , … , 𝑿𝐾  where K > 2. Here, the goal is to find 
𝒖1, … , 𝒖𝐾  which maximizes ∑ 𝒖𝑖
𝑇𝑿𝑖
𝑇𝑿𝑗𝒖𝑗𝑖<𝑗  subject to  ‖𝒖𝑖‖
2  ≤ 1, 𝑃𝑖(𝒖𝑖) ≤  𝑐𝑖 , where the 𝑃𝑖 s are again 
convex penalty functions.     
The algorithm proposed by Witten and Tibshirani (2009) for calculating the canonical covariate of the SCCA 
is as follows: 
1. Initialize 𝒘𝟐to have L1 norm 1. 
2. Iterate the following two steps until convergence: 
(a) 𝒘𝟏 ← arg 𝑚𝑎𝑥𝒘𝟏𝒘𝟏
𝑻𝑿𝟏
𝑻𝑿𝟐 𝒘𝟐 subject to ‖𝒘𝟏‖
2 ≤ 1, 𝑃1(𝒘𝟏) ≤ 𝑐1. 
(b) 𝒘𝟐 ← arg 𝑚𝑎𝑥𝒘𝟐𝒘𝟏
𝑻𝑿𝟏
𝑻𝑿𝟐 𝒘𝟐 subject to ‖𝒘𝟐‖
2 ≤ 1, 𝑃2(𝒘𝟐) ≤ 𝑐2. 







where 𝛥1 = 0, ‖𝒘𝟏‖1 ≤ 𝑐1 ; otherwise, 𝛥1 ≥ 0chosen so that  ‖𝒘𝟏‖1 = 𝑐1 . Here S(.) is a soft-threshold 
operator; that is 𝑆(𝒘𝟏, 𝑐) = 𝑠𝑖𝑔𝑛(𝒘𝟏)(⌊𝒘𝟏⌋ − 𝑐)+. 
In our application 𝑿1 consists of the gene expression measurements of the predicted miRNA target transcripts, 
and 𝑿2 consists of the miRNA expression measurements at corresponding time points.  In each case, the 
columns represent the different miRNAs / mRNAs and the rows are the values from different subjects. Since 
our goal is to find combinations of miRNA and mRNA measurements which are maximally negatively 
correlated, the variables in 𝑿1 and 𝑿2 will be standardized to have mean zero and standard deviation one and 
then either 𝑿1 or 𝑿2 will be multiplied by negative one prior to application of SCCA. Application of SCCA 
to these transformed matrices will identify linear combinations of the original 𝑿1  and 𝑿2  which have 
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maximum negative correlation. As stated previously, the goal of SCCA is to find unit vectors 𝒖 and 𝒗 such 
that 𝒖𝑇𝑿1
𝑇𝑿2𝒗 is maximized subject to constraints on 𝒖 and 𝒗. In our problem, since neither matrix of 
miRNA or mRNA expression measurements is ordered the lasso penalty will be used for both weight vectors 
𝒖 and 𝒗. One exception is that, when the number of miRNAs is small (e.g., ten or fewer), we may use no 
penalty for the miRNA data and retain all the miRNAs in the analysis. Further, for interpretation purposes 
and for construction of our GSEA statistic described below the weights are constrained to be non-negative. 
A permutation procedure will be used for both selecting the optimal set of tuning parameters (c1 and c2) and 
determining the significance of the correlation between the canonical variables 𝑿1𝒖 and 𝑿2𝒗. This procedure 
is advantageous for small samples, since it does not require cross-validation or splitting the sample into 
training and test sets. Subsequent canonical variables can be obtained by applying the procedure to the 
components of 𝑿1 and 𝑿2 which are orthogonal to the previously obtained canonical variables. The SCCA 





2.2. Gene set enrichment analysis (GSEA)  
Gene Set Analysis (GSA) is a method for estimating the significance of predefined gene sets, rather than 
individual genes. The gene sets could be derived from different sources, for example the sets of genes 
representing various biological pathways of cells (e.g., Gene Ontology , KEGG (Kanehisa, et al., 2004), 
Biocarta (http://www.biocarta.com), Reactome (http://www.reactome.org), MSigDB (Subramanian, et al., 
2005), Pathway Interaction Database (Schaefer, et al., 2009)). The motivation behind GSA is that these genes 
inside the gene sets are closely related and will have similar expression patterns. Hence, there is potential for 
increased statistical power as well as biological interpretability because of the strong relationships between 
genes within the same gene set.  
The GSA method works roughly as follows. Suppose we have N genes in the data. The initial step is to 
calculate a test statistic for each of the genes, e.g. for studies concerning two sets of samples (diseased and 
control samples) the two sample t-statistic ti (or some variant thereof) is appropriate. The next step is to 
identify the predefined gene sets for all N genes which are denoted 𝐺𝑆𝐾 = (𝑔𝑠1, 𝑔𝑠2, … , 𝑔𝑠𝐾). In GSA we 
use a cut-off for the 𝑡𝑖 (e.g, a threshold for the p-value of the test statistics) to obtain a gene list, and then test 
for association between this gene list and each of the pre-defined gene sets 𝑠1, … , 𝑠𝑘 using Fisher’s exact test. 
An example 2x2 table for GSA is given in Table 2.1, where N = a + b + c + d. Results can be ordered based 
on the p-value from Fisher’s exact test or on the fold-enrichment 
𝑎/(𝑎 + 𝑏)
(𝑎 + 𝑐)/(𝑏 + 𝑑)⁄  of the 
statistically significant gene list for genes from the given gene set. Note that statistically significant results 
can also be found for gene sets having an under- representation within the list of statistically significant genes, 






In Gene set Not in Gene set 
Significant a b 
Not significant c d 
 
Table 2.1: Example 2x2 table for GSA based on Fisher's test. Letters represent counts in each cell 
An extension to GSA, termed gene set enrichment analysis (GSEA), has an advantage over GSA in that the 
user does not have to specify a significance threshold for inclusion of genes within the gene list but instead 
uses the entire range of information in the collective set of test statistics (Subramanian, et al., 2005). We 
begin with a predefined collection of gene sets 𝐺𝑆𝐾 = (𝑔𝑠1, 𝑔𝑠2, … , 𝑔𝑠𝐾) and compute a test statistic (e.g., a 
t-statistic) 𝑡𝑗 for all 𝑁 genes in our data. Let 𝑻𝑘 = (𝑡1, 𝑡2, . . . , 𝑡𝑛𝑘) be the gene scores for the 𝑛𝑘 genes in gene 
set 𝑔𝑠𝑘. Then, a gene set score (statistic) 𝑔𝑠𝑘(𝑻𝑘) is computed for each gene set 𝑔𝑠𝑘. For Subramanian’s 
original GSEA this was equal to a signed and weighted version of the Kolmogorov-Smirnov statistic, but 
later authors proposed simpler alternative statistics for 𝑔𝑠𝑘(𝑻𝑘)  including the mean of 𝑻𝑘  (Jiang and 
Gentleman, 2007; Tian, et al., 2005). The idea of characterizing the significance of a gene set is that if some 
or all of the gene set scores within 𝑔𝑠𝑘 are higher (or lower) than expected, their sum of scores 𝑻𝑘 will be 
higher (or lower) than expected. The statistical significance of the gene set scores 𝑔𝑠𝑘(𝑻𝑘) can be determined 
by either permuting the gene scores 𝑡𝑗 or by permuting the phenotypes across the samples and re-calculating 
the gene scores. The former addresses the null hypothesis that the scores in a given gene set do not differ 
from the scores outside of the gene set (the so-called competitive test), while the latter addresses the null 
hypothesis that the gene set does not contain genes whose expression levels are associated with the phenotype 
(the self-contained test) (Tian, et al., 2005). In general, the GSEA method has three specific steps: (1) rank 
all genes with some kind of score for each gene, (2) define a specific overall test statistic for each pre-




2.3. GSEA score based on integrating miRNA / mRNA expression data 
A modified version of GSEA which combines both mRNA and miRNA gene expression measurements is 
constructed based on the SCCA. The GSEA is based on a novel statistic constructed from the two sets of 
weight vectors 𝒖 and 𝒗 obtained from SCCA, with constraints that both 𝒖 and 𝒗 are non-negative. We first 
use function CCA.permute in R package PMA provided by  
(https://cran.r-project.org/web/packages/PMA/PMA.pdf) to obtain the best penalties for both mRNA and 
miRNA data sets. This function automatically selects best penalties for sparse CCA using the penalized 
matrix decompostion. The penalties are selected using a permutation procedure for each predetermined 
penalty value. After the permutation process, the function give z-statistic and p-value for each pair of 
canonical variables resulting from a given predetermined penalty value. The best penalties should have both 
a significant p-value (< 0.05) and best z-statistic (larger z-statistic correspond to better tuning parameter 
values). When the data sets are highly correlated, the CCA.permute function may return a very small penalty 
(a smaller penalty means fewer non-negative values in the 𝒖 and 𝒗 weight vectors are obtained). In this case, 
we can use the one standard error rule which is generally used within cross-validation. That is, we select the 
largest penalty value that has a z-statistic within one standard deviation of the optimal penalty z-statistic (that 
is, within the optimal z-statistic minus 1). Then, we apply the new penalty to SCCA to obtain weight vectors 
𝒖 and 𝒗. After we get the first pair of canonical vectors, a second pair of canonical vectors could be obtained 
from the residual matrices of mRNA and miRNA. 𝑿𝟏





𝒓𝒆𝒔𝒊𝒅𝒖𝒂𝒍 = 𝑿𝟐 − ?̂?𝟐 ,  ?̂?𝟐 = 𝑿𝟐𝒗((𝑿𝟐𝒗)
′𝑿𝟐𝒗)
−𝟏(𝑿𝟐𝒗)
′ . Where 𝑿1  indicates mRNA data, 𝑿2 
indicates miRNA data,  𝒖  and 𝒗  are weight vectors obtained from SCCA. Then, we 
apply 𝑿𝟏
𝒓𝒆𝒔𝒊𝒅𝒖𝒂𝒍 𝑎𝑛𝑑 𝑿𝟐
𝒓𝒆𝒔𝒊𝒅𝒖𝒂𝒍 with the same procedure of the original mRNA and miRNA data sets to 
obtain the second pair of canonical vectors. We repeat the procedure above until no significant tuning 
parameter is found by the CCA.permute function. Specifically, after application of SCCA we obtain multiple 
weight vectors 𝒖1, … , 𝒖𝑘 and 𝒗1, … , 𝒗𝑘where 𝒖𝒊 = (𝑢1, 𝑢2, … , 𝑢𝑝1) for the weights associated with mRNAs 
and non-negative weight vector 𝒗𝒊 = (𝑣1, 𝑣2, … , 𝑣𝑝2) for the weights associated with miRNAs, 𝑖 = 1, 2 … 𝑘. 
Then, the 𝒖 and 𝒗 vectors are the summation of multiple weight vectors 𝒖1, … , 𝒖𝑘 and 𝒗1, … , 𝒗𝑘 separately. 
The test statistic is constructed from two parts. The first part consists of the normalized 𝒖 vector 𝒖norm, such 
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that the mean of 𝒖norm is zero and the variance is one. This component simply indicates the degree to which 
each putative target gene is represented in the weight vector 𝒖. The second part consists of the weight vector 
𝑣 multiplied with the putative target matrix 𝑷𝑝2×𝑝1 , where 𝑃𝑖𝑗  = 1 if miRNA 𝑖 putatively targets gene 𝑗 and 
is zero otherwise. This part is calculated as 𝒗∗ =  𝒗𝑇𝑷, where the dimension of 𝒗∗ is 1 × 𝑝1. This component 
incorporates the weights associated with each miRNA into the per-gene scores, and also accounts for the 
degree of targeting associated with each miRNA / mRNA. The 𝒗∗ scores are also normalized to have mean 
zero and standard deviation one (𝒗norm
∗ ). Under the null hypothesis miRNA and mRNA are not correlated, 
which means 𝒖norm scores are independent to 𝒗norm
∗ . Both 𝒖norm and 𝒗norm
∗  scores have mean 0 and standard 
deviation 1. Although we do not know the distribution of these scores, we could also normalize the 
summation of 𝒖norm and 𝒗norm
∗  scores to have mean 0 and standard deviation one. So we set the final statistic 
associated with each gene by summing the normalized 𝒖 and 𝒗∗ scores and then dividing by √2, which is 




∗ ).   
Then, we calculate an aggregate gene enrichment score for each gene set, where the gene sets are pre-
determined from e.g. the KEGG and GO databases. Specifically, suppose there are K pre-determined gene 
sets with 𝑛1, 𝑛2, … , 𝑛𝐾 genes in each set. In our terminology, the vector 𝒁𝑗consists of the components of 𝒁 
corresponding to the genes in gene set 𝑗. Then, the GSEA statistic 𝑔𝑠1(𝒁1),  𝑔𝑠2(𝒁2), … , 𝑔𝑠𝐾(𝒁𝐾) for each 
gene set is calculated by the sum of the per gene statistic included in each gene set then divided by the square 
root of the number of genes in each gene set:  







where 𝑘 = 1,2, … , 𝐾 and 𝒁𝑘 = (𝑧1,  𝑧2, … ,  𝑧𝑛𝑘) are the gene statistics for gene set 𝑔𝑠𝑘. 
The motivation for using this statistic is that under the null hypothesis of no association between 𝑿1and 𝑿2, 
each component of 𝒁𝐾  is expected to have mean 0 and standard deviation 1. Presuming that the components 
of 𝒁𝐾  are also independent under the null, then the statistic 𝑔𝑠𝑘(𝒁𝑘) is also expected to have mean 0 and 
standard deviation 1. While the distribution of 𝑔𝑠𝑘(𝒁𝑘) is unknown, the gene sets scores defined in this 
manner then indicate how many standard deviations away from the null expectation the gene set statistic is. 
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When √𝑛𝑘  gets large enough, the distribution of 𝑔𝑠𝑘(𝒁𝑘)  approximately converges to asymptotic 
normal 𝑁(0,1). 
Finally, we calculate the permutation p-value of the GSEA statistic for each gene set using both the 
competitive test and the self-contained test. For the competitive test, we first resample the per-gene statistics 
𝒁 = (𝑧1,  𝑧2, … ,  𝑧𝑝1) without replacement to obtain permuted statistics 𝒁
𝑚 for 𝑚 = 1, … , 𝑀 permutations. 




𝑚), … , 𝑔𝑠𝐾
𝑚(𝒁𝐾
𝑚)  are calculated for each of the original 
gene sets, where 𝒁𝑘
𝑚 = (𝑧1
𝑚,  𝑧2
𝑚, … , 𝑧𝑛𝑘
𝑚 )  are the permuted gene statistics for each gene set  𝑔𝑠𝑘 . The 
permutation p-value 𝑝perm,𝑘 for each gene-set 𝑘 is then calculated as the proportion of the permuted GSEA 
statistics that are larger than the original GSEA statistic:  








𝑚) > 𝑔𝑠𝑘(𝒁𝑘)) , 
where 𝐼(⋅) is the indicator function. 
For the self-contained test, we resample the samples of the mRNA data set without replacement to obtain 
permuted mRNA data. Then, we apply SCCA on the permuted mRNA data and original miRNA data to get 
permuted statistics vector 𝒖𝑚  and vector 𝒗𝑚  for 𝑚 = 1, … , 𝑀 permutations. Then, a permuted per gene 
statistic 𝒁𝑚𝑠 is calculated by 𝒖𝑚 and 𝒗𝑚 using the same procedure as we used to calculate the Z score in the 





𝑚𝑠), … , 𝑔𝑠𝐾
𝑚𝑠(𝒁𝐾




𝑚𝑠, … , 𝑧𝑛𝑘
𝑚𝑠) are the self- contained permuted gene statistics for gene set 𝑔𝑠𝑘. The permutation p-value 
𝑝self-perm,𝑘 for each gene-set 𝑘 is then calculated as the proportion of the permuted GSEA statistics that are 
larger than the original GSEA statistic:  








𝑚𝑠) > 𝑔𝑠𝑘(𝒁𝑘)) , 




2.4. Integrated analysis of miRNA and mRNA expression data based on pairwise correlation analysis 
For comparison purposes, we construct a pairwise correlation (PWC) GSEA statistic based on the pairwise 
Pearson product-moment correlation coefficients between the mRNA (matrix 𝑿1) and miRNA (matrix 𝑿2) 
expression measurements. Let 𝐐𝑋2𝑋1 denotes the sample correlation matrix between 𝑿2 and 𝑿1 (which we 
abbreviate as 𝐐 in what follows).  To construct the per-gene statistics used for the PWC approach, we filter 
𝐐 in the following manner.  First, all the non-negative correlations are set to be zero.  Second, all correlation 
coefficients with adjusted p-values (based on the Benjamini- Hochberg method for controlling the false 
discovery rate) above a predetermined level 𝛼 are set to be zero as well. Then, we denote the filtered 𝐐 matrix 
as 𝐐∗. In essence, 𝐐∗ contains only significant (after controlling for multiple comparisons) pairwise negative 
correlations between miRNAs and mRNAs (all other elements are zero). This matrix is then multiplied 
element-wise with the putative target matrix 𝑷𝑝2×𝑝1  which we create in SCCA section and the final PWC 
per-gene statistics obtained as 𝐙pwc
T =  𝑝1
−1𝟏T𝐐∗ ∘ 𝑷, where ∘ denotes the Hadamard product and 𝟏T is a 
vector of ones of length 𝑝1. The GSEA statistic is calculated as the mean of the 𝑧pwc values for each gene set, 
as in the SCCA method. The permutation p-value was calculated by the same process as competitive test for 
the SCCA method. The function rcorr in R package Hmisc (Harrell, 2014) was used to calculate the sample 




SIMULATION OF INTEGRATED ANALYSIS OF MIRNA AND MRNA EXPRESSION 
 
3.1 Simulation Strategy 
The goal of the simulation study was to compare the ability of the SCCA and PWC methods to detect 
statistically significant gene sets (e.g., biological pathways) between two sets of variables from mRNA and 
miRNA population data sets. We use the same approach as (Witten and Tibshirani, 2009) to simulate 
correlated miRNA and mRNA sample data, while the approach to simulating gene sets was adopted from 
(Efron and Tibshirani, 2007) and (Abatangelo, et al., 2009). Here 𝑿1 is a 𝑛 × 𝑝1 matrix consisting of the 
mRNA expression measurements and 𝑿2  is a 𝑛 × 𝑝2  matrix of miRNA expression measurements on the 
same set of subjects. We presume that only the first 𝑟1 variables in 𝑿1 are highly correlated with the first 𝑟2 
variables in 𝑿2, while the rest of the variables in 𝑿1 and 𝑿2 are uncorrelated. The data sets are simulated as 
follows.  First, we generate a latent random vector for both data sets 𝜸 = [𝛾1, 𝛾2, . . . , 𝛾𝑛]
𝑇  from 𝑁(0, 𝜎𝛾
2𝑰𝑛), 
where 𝑰𝑛  is the 𝑛 × 𝑛  identify matrix.  Then, we generate vectors 𝒖 ∈  ℝ
𝑝1  and 𝒗 ∈  ℝ𝑝2  where 
𝑢1, 𝑢2, … , 𝑢𝑟1 are independent and identically distributed (iid) 𝑁(𝜇𝑢, 𝜎𝑢
2), 𝑣1, 𝑣2, … , 𝑣𝑟2are iid 𝑁(𝜇𝑣, 𝜎𝑣
2), and 
the remaining elements in 𝒖 and 𝒗 are set to zero. The vectors 𝒖 and 𝒗 are the weights used to determine the 
linear combination of measurements in 𝑿1 and 𝑿2 which are maximally inversely correlated with each other. 
So, the values in each data set are generated as follows: 
𝑥1𝑖𝑗 =  𝑢𝑗𝛾𝑖 + 𝑒1𝑖𝑗 for 𝑖 = 1, … , 𝑛 and 𝑗 = 1, … , 𝑝1 , 
𝑥2𝑖𝑗 =  −𝑣𝑗𝛾𝑖 +  𝑒2𝑖𝑗 for 𝑖 = 1, … , 𝑛 and 𝑗 = 1, … , 𝑝2 , 
where 𝑒1𝑖𝑗 and 𝑒2𝑖𝑗 are both 𝑁(0, 𝜎𝑒
2). The negative sign for the product −𝑣𝑗𝛾𝑖 ensures negative correlation 
between the 𝑟1 variables in 𝑿1 and the 𝑟2 variables in 𝑿2, as long as the parameters for the distributions of 𝒖 
and 𝒗 are chosen appropriately. 
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Lastly, we simulated the putative target matrix 𝑷𝑝2×𝑝1  which determines whether miRNA 𝑖 putatively targets 
gene 𝑗 (𝑃𝑖𝑗  = 1) or not (𝑃𝑖𝑗 = 0).  First, for each of the 𝑖  miRNAs the number of targeted genes is simulated 
by an integer uniform random number 𝑛target,i  between 𝑛target,min  and 𝑛target,max . Second, which genes are 
targeted by each miRNA is simulated. For the 𝑝2 –  𝑟2 unassociated miRNAs these are generated as a random 
sample without replacement of 𝑛target,i genes from the 𝑝1total number of genes. For the 𝑟2 associated miRNAs 
a fraction 𝑝related of the targets are randomly selected from the 𝑟1 associated genes, and the remaining are 
randomly selected from the 𝑝1 –  𝑟1 other genes. 
 
3.2 Simulation study results – single gene set  
Our initial simulation study consisted of a single significant gene set having inversely correlated mRNA and 
corresponding targeting miRNA expression measurements. The total number of genes (mRNAs) was set to 
1000, the total number of miRNAs to 50, and we assumed 50 gene sets each consisting of 20 genes within 
each set.  All other parameters were fixed.  Details of the simulation study parameters are given in Table 3.1. 
P-values for the significance of each gene set based on the SCCA and PWC approaches were calculated based 
on the competitive test permutation procedures outlined in Sections 2.1 and 2.2, respectively, with adjustment 
for multiple comparisons based on the Benjamini-Hochberg method (Benjamini and Hochberg, 1995) for 
controlling the false discovery rate. Power for each method was calculated as the proportion of times out of 
100 replicates that the associated gene set was declared significant (adjusted p-value < 0.05). The type I error 
rate for each method was calculated as the proportion of times out of 100 replicates that the remaining gene 
sets were declared significant. The simulation studies were performed based on 100 replications and the 
averaged results are presented in figures (3.1- 3.6).  
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Table 3.1: Summary of Parameters in Simulation Studies 
Parameters Description  Value 
n  Sample Size  10, 20, 30, 40, 50 
𝑝1 Total number of mRNAs 1000  
𝑝2 Total number of miRNAs 50 
𝑟1 Number of related mRNAs 5, 10 and 20 
𝑟2 Number of related miRNAs 1, 5 and 20 
𝑛𝑔𝑠 Number of gene sets 50  
𝑛𝑔 Number of genes in each gene set 20 
𝜇𝑢, 𝜇𝑣  Mean for weight vector for 
related mRNAs and miRNAs 
𝜇𝑢 =  𝜇𝑣 = 1  
𝜎𝛾  Standard deviation for latent 
vector relating miRNAs and 
mRNAs 
1 
𝜎𝑢  Standard deviation for weight 
vector for related mRNAs 
0.1 
𝜎𝑣  Standard deviation for weight 
vector for related miRNAs 
0.2 
𝜎𝑒  Standard deviation for error of 
expression measurements (both 
miRNA and mRNA) 
0.5, 1, 1.5 
𝑛target,min Minimum number of putative 
targets for each miRNA 
25 
𝑛target,max Maximum number of putative 
targets for each miRNA 
40 
𝑝related From the 𝑟2  associated miRNAs 
the fraction of targets selected 
from the 𝑟1 associated genes 
0.5 
𝛼 Threshold for PWC method 0.05 
 
Figure 3.1- 3.2. show the results for the simulated data sets where the parameters of the simulated data sets 
were number of related mRNAs 𝑃1 = 5 for all nine data sets, and number of related miRNAs 𝑃2 = 1, 5, 20  
respectively for three of the nine data sets, each row of the plot represents the power of data sets with same 
number of related miRNAs (e.g. first row of plots indicated the three data sets with related miRNAs equaled 
to 20). The columns of the figure represent the power of data sets with different error rates for both miRNA 
and mRNA data sets. In the figure, the x-axis represents the number of samples in each data set (i.e. 𝑛= 10, 
20, 25, etc.), and the y-axis indicates the power or the error rate of detecting the gene sets for each method. 
The solid lines with triangles represent the power or error rate under each sample size for the SCCA method 
and the dotted lines with circles indicate the power or error rate under each sample size for the PWC method. 
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Figures 3.1- 3.2 indicate the power and error rate of the data sets with correlated miRNAs equal to 1, 5 and 
20 respectively shown in each row. For figure 3.1, we can see that under the conditions related miRNA 
equaled to 1, 𝜎𝑒 = 0.5 and 𝜎𝑒 = 1, except the sample size of the data equal to 10 for 𝜎𝑒 = 1, the power of 
the pair wise correlation method is larger than the SCCA method. Also, the power of PWC is larger than 
SCCA when related miRNAs are equal to 5, 𝜎𝑒 = 0.5 and the sample size equal to 25. However, under other 
conditions the power of SCCA method is larger than power of PWC. Second, we can also see that the power 
increased with sample size for both methods and that the power increases when the number of targeting and 
correlated miRNAs increases. Opposite, the power decreases with increasing standard deviation of 
expression measurements for both mRNA and miRNA under same sample size. Figure 3.2 is the error rate 
for both SCCA and PWC methods. We can see that the error rate of the PWC method equals zero under every 
condition. And the error rate for the SCCA method is also small. The largest value of the error rate is 0.002 
which is considerably less than 0.05. We can conclude that while the nominal error rate is not exceeded by 
either method, the methods may be lacking power due to being overly conservative.  
Figures 3.3- 3.4 show the results for the simulated data sets where the parameters of the simulated data sets 
were number of related mRNAs 𝑃1 = 10 for all the nine data sets. And other settings were the same as the 
simulated data sets corresponding to Figure 3.1.  
Figures 3.3- 3.4 indicate the data sets with correlated mRNAs equal to 10. For Figure 3.3, we can see that the 
power of PWC is larger than SCCA only when related number of miRNA= 1 and 𝜎𝑒 = 0.5 and 𝜎𝑒 = 1. For 
other conditions power of pair wise correlation method is less than or equal to the SCCA method. Other 
results are similar to Figure 3.1. Figure 3.4 is the error rate for both SCCA and PWC methods. The results 
are similar to Figure 3.2. The largest value of error rate is 0.0012 which is less than 0.05.  
Figures 3.5 and 3.6 show the results for the simulated data sets where the parameters of the simulated data 
sets were number of related mRNAs 𝑃1 = 20 for all the nine data sets. And other settings were the same as 
the simulated data sets corresponding to Figure 3.1.  
Figures 3.5 and 3.6 indicate the data sets with correlated mRNAs equal to 20. For figure 3.5, the result is 
similar to figure 3.3. The figure 3.6 is the error rate for both SCCA and PWC methods. We can see that the 
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error rate of PWC method equals to 0 under every condition. And the error rate for SCCA method is also 
small. The largest value of error rate is 0.0016 which is less than 0.05.  
In comparing the two methods, the PWC method has larger power than the SCCA when the number of 
miRNAs is small. But it changes when the number of associated miRNAs increases. This separation is 
greatest when the subset size is small and the standard deviation is large, with the power of the methods 
rapidly converging to each other as the sample size increases. Also, we can conclude that the power increases 
as the number of related mRNAs and miRNAs increases. The error rates of both methods are small for all 




Figure 3.1. The average power of both pair-wise correlation and SCCA methods over 100 simulated data sets. 
In each data set, there were five correlated mRNAs, where 𝑃1 = 5, 𝑟2 = 995. There are 9 plots in the figure, 
where 𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related miRNAs equal 
to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of observations in each 
data set (i.e. 𝑛 =5, 15, 25, etc.), and y- axis indicates the power of detecting the correlated genes by two 
methods. The dotted lines indicate the power under each sample size for PWC. The solid line indicated power 




Figure 3.2. The average error rate of both pair-wise correlation and SCCA methods over 100 simulated data 
sets. In each data set, there were five correlated mRNAs, where 𝑃1 = 5, 𝑟2 = 995. There are 9 plots in the 
figure, where 𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related miRNAs 
equal to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of observations in 
each data set (i.e. 𝑛 = 5, 15, 25, etc.), and y-axis indicates the error rate of detecting the correlated genes by 
two methods. The dotted lines indicate the error rate under each sample size for PWC. The solid line indicated 




Figure 3.3. The average power of both pair-wise correlation and SCCA methods over 100 simulated data sets. 
In each data set, there were ten correlated mRNAs, where 𝑃1 = 10, 𝑟2 = 990. There are 9 plots in the figure, 
where 𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related miRNAs equal to 
1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of observations in each data 
set, and y-axis indicates the power of detecting the correlated genes by two methods. The dotted lines indicate 




Figure 3.4. The average error rate of both pair-wise correlation and SCCA methods over 100 simulated data 
sets. In each data set, there were ten correlated mRNAs, where 𝑃1 = 10, 𝑟2 = 990. There are 9 plots in the 
figure, where 𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related miRNAs 
equal to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of observations in 
each data set and y-axis indicates the error rate of detecting the correlated genes by two methods. The dotted 





Figure 3.5. The average power of both pair-wise correlation and SCCA methods over 100 simulated data sets. 
In each data set, there were twenty correlated mRNAs, where 𝑃1 = 20, 𝑟2 = 980. There are 9 plots in the 
figure, where 𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related miRNAs 
equal to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of observations in 
each data set, and y-axis indicates the power of detecting the correlated genes by two methods. The dotted 




Figure 3.6. The average error rate of both pair-wise correlation and SCCA methods over 100 simulated data 
sets. In each data set, there were twenty correlated mRNAs, where 𝑃1 = 20, 𝑟2 = 980. There are 9 plots in 
the figure, where  𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related 
miRNAs equal to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of 
observations in each data set and y-axis indicates the error rate of detecting the correlated genes by two 
methods. The dotted lines indicate the error rate under each sample size for PWC. The solid line indicates 
error rate for SCCA method.  
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3.3. Simulation study results – two gene sets  
The goal of the two data sets simulation study is similar to the one gene set simulation. This simulation study 
consisted of two significant gene sets each having inversely correlated mRNA and corresponding targeting 
miRNA expression measurements. In two gene sets simulation, we generated data sets as follows. We first 
separately created two data sets each with the same parameters and a single significant gene set, then bound 
the two data sets by columns. For each data set, the number of mRNAs was set to 500, the total number of 
miRNAs to 25, and we assumed 25 gene sets each consisting of 20 genes within each set. All other parameters 
were fixed.  Details of the simulation study parameters are given in Table 3.2. P-values for the significance 
of each gene set based on the SCCA and PWC approaches were calculated based on the competitive test 
permutation procedures outlined in Sections 2.1 and 2.2, respectively, with adjustment for multiple 
comparisons based on the Benjamini-Hochberg method (Benjamini and Hochberg, 1995) for controlling the 
false discovery rate. Power for each method was calculated as the proportion of times out of 100 replicates 
that the associated gene set was declared significant (adjusted p-value < 0.05). The type I error rate for each 
method was calculated as the proportion of times out of 100 replicates that the remaining gene sets were 
declared significant. The simulation studies were performed based on 100 replications and the averaged 




Table 3.2: Summary of Parameter in Simulation Studies for each data pair 
Parameters Description Value 
n  Sample Size  10, 20, 30, 40, 50 
𝑝1 Total number of mRNAs 500  
𝑝2 Total number of miRNAs 25 
𝑟1 Number of related mRNAs 5, 10 and 20 
𝑟2 Number of related miRNAs 1, 5 and 20 
𝑛𝑔𝑠 Number of gene sets 25  
𝑛𝑔 Number of genes in each gene set 20 
𝜇𝑢, 𝜇𝑣 Mean for weight vector for 
related mRNAs and miRNAs 
𝜇𝑢 =  𝜇𝑣 = 1  
𝜎𝛾  Standard deviation for latent 
vector relating miRNAs and 
mRNAs 
1 
𝜎𝑢  Standard deviation for weight 
vector for related mRNAs 
0.1 
𝜎𝑣  Standard deviation for weight 
vector for related miRNAs 
0.2 
𝜎𝑒  Standard deviation for error of 
expression measurements (both 
miRNA and mRNA) 
0.5, 1, 1.5 
𝑛target,min Minimum number of putative 
targets for each miRNA 
25 
𝑛target,max Maximum number of putative 
targets for each miRNA 
40 
𝑝related From the 𝑟2  associated miRNAs 
the fraction of targets selected 
from the 𝑟1 associated genes 
0.5 
𝛼 Threshold for PWC method 0.05 
 
Figures 3.7 and 3.8 show the results for two data set simulations, where the parameters for both data sets 
were number of related mRNAs 𝑃1 = 5 for all nine data sets, and number of related miRNAs  𝑃2 =
1, 5, 20 respectively for each corresponding to a single row in the figure. The parameters indicated that there 
were 5 correlated mRNAs included in each data set and 1, 5 and 20 correlated miRNAs respectively in each 
data. In each figure, the x-axis represents the sample size in each data set (i.e. 𝑛= 10, 20, 30, etc.), and the y-
axis indicates the power or the error rate of detecting the gene sets by the two methods. The solid lines with 
triangles represented the power or error rate under each sample size for the SCCA method and the dotted 
lines with circles mean the power or error rate under each sample size for the PWC method. 
Figures 3.7- 3.8 indicate the power and error rate of the data set with correlated mRNAs equal to 5 and 
correlated miRNAs equal to 1, 5 and 20 which respectively correspond to rows of Figure 3.7. We can see 
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that under the conditions when the related miRNAs is one and 𝜎𝑒 = 0.5, the power of pair wise correlation 
is larger than that for SCCA for all the sample sizes. And for 𝜎𝑒 = 1, under the condition that sample sizes 
of the data sets equal to 10 and 20, the average power of the PWC method is less than the SCCA method.  
But when the sample size is larger than 20, the average power of PWC is larger than the average power of 
the SCCA method. However, under other conditions the power of PWC is smaller than SCCA for all the 
sample sizes. We can also see that the power increases as the sample size increases and the number of related 
miRNAs increase for both methods. Opposite, the power decreases with increasing standard deviation of 
expression measurements for both mRNA and miRNA under the same sample size. Figure 3.8 is the error 
rate for both SCCA and PWC methods. We can see that the error rate of the PWC method is zero under every 
condition and the error rate for the SCCA method is also small. The largest value of error rate is 0.018 which 
is less than 0.05. Hence similar conclusions hold as with the single gene set simulation study.   
Figure 3.9 and 3.10 show the results for two data sets simulation, where the parameters for both data sets 
were 𝑃1 = 10 for all nine data sets, and  𝑃2 = 1, 5, 20 respectively. The parameters indicate that there were 
10 correlated mRNAs included in each data set and 1, 5 and 20 correlated miRNAs respectively in each data. 
And other settings were the same as the simulated data sets corresponding to Figure 3.7.    
Figures 3.9- 3.10 indicate the power and error rate of the data set with correlated mRNAs equal to 10 and 
correlated miRNAs equal to 1, 5 and 20 which respectively corresponds to rows of Figure 3.9. The result of 
power of Figure 3.9 is similar to that for Figure 3.7. The Figure 3.10 is the error rate for both SCCA and 
PWC methods. We can see that the result is similar to Figure 3.8, error rate of PWC method equals to 0 under 
every condition. And the largest value of error rates is 0.0015 which are less than 0.05.  
Figure 3.11- 3.12 show the results for two data sets simulation, where the parameters for both data sets 
were 𝑃1 = 20 for all nine data sets, and other settings were the same to the simulated data sets corresponding 
to figure 3.7. Looking at Figures 3.11- 3.12, the result of Figure 3.11 is similar to Figures 3.7 and 3.9. The 
Figure 3.12 is the error rate for both SCCA and PWC methods. The result of Figure 3.12 is similar to Figures 
3.8 and 3.10, error rate of PWC method equals to 0 under every condition. And the largest value of error rates 
is 0.0015 which are less than 0.05.  
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Over all conditions, several general observations can be concluded by looking at the figures. First, both power 
of SCCA and PWC increase with increasing sample size and number of miRNAs and mRNAs, as expected. 
Opposite, the power decreases and as the error rate increases with increasing standard deviation of expression 
measurements for both mRNAs and miRNAs. 
In comparing the two methods, the PWC method has larger power than SCCA only when the number of 
miRNAs is equal to 1, 𝜎𝑒 = 0.5, and 𝜎𝑒 = 1 with a small sample size. But it changes as the number of 
miRNAs associated with the mRNAs in the gene set increases. This separation is greatest when the subset 
size is small and the standard deviation is large, with the power of both methods rapidly converging to each 
other as the subset size increases. The error rates of both methods are small for all conditions and possibly 





Figure 3.7. The average power of both pair wise correlation and SCCA methods over 100 two data sets 
simulation. In each data set, there were five correlated mRNAs, where 𝑃1 = 5, 𝑟2 = 495. There are 9 plots 
in the figure, where 𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related 
miRNAs equal to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of 
observations in each data set (i.e. 𝑛 =10, 20, 30, etc.), and y-axis indicates the power of detecting the 
correlated genes by two methods. The dotted lines indicate the power under each sample size for PWC. The 





Figure 3.8. The average error rate of both pair wise correlation and SCCA methods over 100 two data sets 
simulation. In each pair of data sets, there were 5 correlated mRNAs, where 𝑃1 = 5, 𝑟2 = 495. There are 9 
plots in the figure, where 𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related 
miRNAs equal to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of 
observations in each data set (i.e. 𝑛 =5, 15, 25, etc.), and y-axis indicates the error rate of detecting the 
correlated genes by two methods. The dotted lines indicate the error rate under each sample size for PWC. 





Figure 3.9. The average power of both pair wise correlation and SCCA methods over 100 two data sets 
simulation. In each data set, there were ten correlated mRNAs, where 𝑃1 = 10, 𝑟2 = 490. There are 9 plots 
in the figure, where  𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related 
miRNAs equal to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of 
observations in each data set, and y-axis indicates the power of detecting the correlated genes by two methods. 
The dotted lines indicate the power under each sample size for PWC. The solid line indicated power for 




Figure 3.10. The average error rate of both pair wise correlation and SCCA methods over 100 two data sets 
simulation. In each data set, there were ten correlated mRNAs, where 𝑃1 = 20, 𝑟2 = 480. There are 9 plots 
in the figure, where  𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related 
miRNAs equal to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of 
observations in each data set, and y-axis indicates the power of detecting the correlated genes by two methods. 






Figure 3.11. The average power of both pair wise correlation and SCCA methods over 100 two data sets 
simulation. In each data set, there were twenty correlated mRNAs, where 𝑃1 = 20, 𝑟2 = 480. There are 9 
plots in the figure, where 𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related 
miRNAs equal to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of 
observations in each data set, and y-axis indicates the power of detecting the correlated genes by two methods. 






Figure 3.12. The average error rate of both pair wise correlation and SCCA methods over 100 two data sets 
simulation. In each data set, there were twenty correlated mRNAs, where 𝑃1 = 20, 𝑟2 = 480. There are 9 
plots in the figure, where 𝜎𝑒 = 0.5, 𝜎𝑒 = 1 𝑎𝑛𝑑 𝜎𝑒 = 1.5 respectively for each column and number of related 
miRNAs equal to 1, 5 and 20 for each row. In each plot of the figure, x-axis indicates the number of 
observations in each data set, and y-axis indicates the power of detecting the correlated genes by two methods. 






 REAL DATA ANALYSIS 
4.1. Prostate Cancer 
The miRNA and mRNA microarray data sets of human prostate cancer and normal cell we used were 
obtained from the Broad Institute and downloaded from the database:  
(http://www.broadinstitute.org/cgi-bin/cancer/datasets.cgi) (Lu, et al., 2005). The original data set 
contained six prostate cancer tumor and six normal human tissues with both miRNA and mRNA 
expression. The miRNA data was filtered by the minimum value of 32 and log2 transformed, so the 
minimum value was 𝑙𝑜𝑔2(32) = 5. The mRNA data were obtained using Affymetrix Genechips. There 
were two chips used in the data, Hu35KsubA and Hu6800. The data totally contained 16,063 probes which 
respectively 8,934 and 7,129 probes in Hu35KsubA and Hu6800 microarrays. Here, we first chose the 
8,934 probes from Hu35KsubA chip to do the initial analysis.  
In the research, we first filtered the data. For original miRNA data, there were 217 miRNAs and 12 samples 
(6 tumor and 6 normal). We filtered out the 9 miRNAs which had a variance 0 across the samples. In mRNA 
expression data, we chose 8,934 mRNAs probes from Hu35KsubA chips. We used the function nsFilter 
within R package genefilter to filter the mRNA data by removing duplicate probes mapping to the same 
Entrez Gene ID (the probe with the highest variance across the samples was retained) and probes with a 
variance below the 50th percentile. After filtering 2,917 probes remained.  
Second, we determined down regulated differentially expressed miRNAs between normal and tumor samples 
using the empirical Bayes method in R package limma (Ritchie, et al., 2015) and (Smyth, 2004). We 
identified 154 significant miRNAs with adjusted p-values (based on Benjamini-Hochberg correction) ≤ 0.05. 
All of the DE miRNAs were down regulated in the tumor tissue. 
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Third, we determined three lists (see Table 4.1 and Figure 4.1) of target mRNAs which we would use in the 
later gene-set enrichment analysis with DAVID. The first list consisted of putative target genes of the DE 
miRNAs, based on the intersection of targets in the miRBase (Kozomara and Griffiths-Jones, 2014) and 
TargetScan (Lewis, et al., 2003) databases. This resulted in 3,135 putative target genes of the down regulated 
miRNAs. The second list consisted of intersecting this putative target list with the up regulated DE genes. 
We determined up regulated DE genes using the same procedures as for miRNAs. Here we identified 48 up-
regulated and DE (adjusted p-value < 0.05) mRNAs. The intersection of this list with the list of putative 
target genes resulted in 21 total genes. The third list was the overlapped genes between putative target 
mRNAs of miRNAs and significant genes obtained by pair wise correlation method. Here we identified 256 
mRNAs with significant correlation (adjusted p-value < 0.05) between miRNAs and mRNA. The intersection 
of this list with the list of putative target genes resulted in 256 total genes. 
Table 4.1. Description of method of obtaining gene lists 
Method Brief Description 
List 1: Putative target mRNAs for down regulated DE 
miRNAs 
Obtained list of putative targets from down 
regulated DE miRNAs by intersecting putative 
targets from miRBase and TargetScan. Uploaded 
this gene list to DAVID for gene set analysis  
List 2: Intersection of putative targets (List 1) and up 
regulated DE mRNAs 
Obtained gene list by intersecting putative 
target mRNAs (List1) and up regulated DE 
mRNAs of the data set. Uploaded this gene list 
to DAVID for gene set analysis  
List 3: Intersection of putative targets (List 1) and 
significant mRNAs by PWC method 
Obtained gene list by intersecting putative 
target mRNAs (List1) and significant negative 
correlated mRNAs detected by PWC method 
with adjust p-value less than 0.05. Uploaded this 





Down regulated DE miRNAs 
(154 miRNAs) 
List 1: Putative targets (3,135 
genes) 
List 2: Intersection of putative 
targets and up regulated DE 
mRNAs(21 genes ) 
List 3: Intersection of putative 
targets and significant negative 
correlated mRNAs( 256 genes) 
Up regulated DE mRNAs( 48 
genes) 










































After getting the three lists, we used the SCCA method based on the 154 significant down-regulated miRNAs 
data and the 2,963 filtered mRNAs expressed data from Hu35KsubA chip. After normalizing each of the 
matrices so that expression measurements for each miRNA / mRNA had mean zero and standard deviation 
one, the miRNA data was multiplied by -1. The CCA.permute function in package PMA (Witten, et al., 2009) 
was used to determine optimal penalty parameters for SCCA with multiple sets of canonical variables. But 
in the result, only the first set of canonical variables had significant permuted p-value. So, the first set of 
canonical variables were used and there were 46 non-zero elements in the 𝑢 vector, which meant that 31 
mRNAs were selected by the SCCA function. And there were 3 non-zero elements in 𝑣  vector, which 
indicated 3 miRNAs were selected. 
The next step was KEGG pathway analysis with the SCCA GSEA method. We first used the 
GeneSetCollection function within the Bioconductor package GSEABase to construct a collection of gene 
sets of pathways from the KEGG database. There were 217 pathways collected from KEGG. FDR adjusted 
p-values from these pathways are given in Table 4.2, where the permuted p-value was calculated by the self-
contained method.  For comparison purposes, the results from DAVID analysis of the KEGG database with 
default parameters based on all 3,315 putative targets, the intersection of these targets with the 48 DE up-
regulated genes, and the intersection of these targets with the genes significantly correlated with the miRNAs 
are given in Tables 4.3-4.5. The former is based on a huge number of genes and identifying germane 
pathways based on this large set is a daunting task. The middle is based on only 21 genes, and returns only a 




Table 4.2. KEGG pathway analysis by First canonical vector and Self-contained test 
KEGG ID Pathway Statisitc P-value Adj.P-value 
4974 Protein digestion and absorption 2.724 0.005 0.293 
51 Fructose and mannose metabolism 1.908 0.008 0.293 
534 Glycosaminoglycan biosynthesis - heparan sulfate 1.731 0.008 0.293 
520 Amino sugar and nucleotide sugar metabolism 1.387 0.009 0.293 
532 Glycosaminoglycan biosynthesis - chondroitin sulfate 1.168 0.016 0.293 
4672 Intestinal immune network for IgA production 0.330 0.017 0.293 
4973 Carbohydrate digestion and absorption 1.369 0.018 0.293 
100 Steroid biosynthesis 1.085 0.022 0.293 
4970 Salivary secretion 1.433 0.022 0.293 
5332 Graft-versus-host disease 0.230 0.026 0.293 
5221 Acute myeloid leukemia 0.895 0.034 0.293 
4210 Apoptosis 0.844 0.035 0.293 
5020 Prion diseases 0.165 0.036 0.293 
5218 Melanoma 0.821 0.038 0.293 
4664 Fc epsilon RI signaling pathway 0.798 0.043 0.293 
5213 Endometrial cancer 0.722 0.044 0.293 
5214 Glioma 0.757 0.044 0.293 
5223 Non-small cell lung cancer 0.722 0.045 0.293 
5142 Chagas disease (American trypanosomiasis) 0.610 0.048 0.293 
5210 Colorectal cancer 0.691 0.048 0.293 
 
Table 4.2. KEGG pathway found by SCCA and GSEA method in Prostate Cancer data. We list first 20 




Table 4.3. KEGG Pathway analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
hsa04144:Endocytosis 2.10 p<0.001 0.001 
hsa04722:Neurotrophin signaling pathway 2.33 p<0.001 0.001 
hsa04310:Wnt signaling pathway 2.17 p<0.001 0.001 
hsa04330:Notch signaling pathway 2.87 0.001 0.028 
hsa04910:Insulin signaling pathway 1.93 0.001 0.039 
hsa04120:Ubiquitin mediated proteolysis 1.90 0.001 0.040 
hsa04930:Type II diabetes mellitus 2.46 0.007 0.16 
hsa05200:Pathways in cancer 1.44 0.007 0.14 
hsa05211:Renal cell carcinoma 2.07 0.011 0.19 
hsa04010:MAPK signaling pathway 1.45 0.015 0.23 
hsa04012:ErbB signaling pathway 1.89 0.015 0.21 
hsa00510:N-Glycan biosynthesis 2.31 0.017 0.21 
hsa05210:Colorectal cancer 1.84 0.024 0.27 
hsa04916:Melanogenesis 1.75 0.024 0.25 
hsa04520:Adherens junction 1.88 0.025 0.24 
hsa00730:Thiamine metabolism 4.82 0.041 0.36 
hsa04530:Tight junction 1.51 0.06 0.44 
hsa04140:Regulation of autophagy 2.21 0.06 0.46 
hsa05215:Prostate cancer 1.63 0.07 0.48 
hsa04070:Phosphatidylinositol signaling system 1.70 0.08 0.48 
 
Table 4.3. KEGG pathways found by DAVID online software in Prostate Cancer data. We analyzed predicted 
target gene list of 154 significant down regulated miRNAs by DAVID. The putative target list contained 




Table 4.4. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
hsa04150:mTOR signaling pathway 27.94 0.06 0.90 
 
Table 4.4. KEGG pathway found by DAVID online software in Prostate Cancer data. We analyzed 
intersection gene list of predicted target gene list and up-regulated mRNAs by DAVID. The intersection list 
contained 21 genes. There was only one pathway found. 
 
 
Table 4.5. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
hsa04330:Notch signaling pathway 8.07 0.003 0.27 
hsa04150:mTOR signaling pathway 7.30 0.004 0.21 
hsa04910:Insulin signaling pathway 3.94 0.008 0.24 
hsa05200:Pathways in cancer 2.31 0.025 0.48 
hsa05220:Chronic myeloid leukemia 4.05 0.07 0.80 
hsa05210:Colorectal cancer 3.61 0.09 0.83 
 
 
Table 4.5. KEGG pathway found by DAVID online software in Prostate Cancer data. We analyzed 
intersection gene list of predicted target gene list and mRNAs found by pair wise correlation method of 154 
significant down regulated miRNAs by DAVID. The intersection list contained 256 genes and there were six 




Then, we produced a similar analysis based on the GO database. FDR adjusted p-values for these pathways 
corresponding to the GSEA statistic resulting from the SCCA method are given in Table 4.6. For comparison 
purposes, the results from DAVID analysis of the GO database with default parameters based on all 3,135 
putative targets, the intersection of these targets with the 48DE up-regulated genes and the intersection of 
putative target genes with significant pair-wise correlations are given in Tables 4.7- 4.9.   
Table 4.6. GO pathway analysis by First canonical vector and Self-contained test 
GO ID GO Term Statisitc P-value Adj.P-value 
GO:0016874 ligase activity 4.706 p<0.001 0.327 
GO:0018024 histone-lysine N-methyltransferase activity 6.489 p<0.001 0.372 
GO:0004514 
nicotinate-nucleotide diphosphorylase 
(carboxylating) activity 7.708 0.001 0.372 
GO:0006469 negative regulation of protein kinase activity 4.412 0.001 0.372 
GO:0030278 regulation of ossification 6.947 0.001 0.372 
GO:0007422 peripheral nervous system development 5.632 0.002 0.372 
GO:0008045 motor neuron axon guidance 5.632 0.002 0.372 
GO:0019674 NAD metabolic process 5.416 0.002 0.372 
GO:0035284 brain segmentation 6.995 0.002 0.372 
GO:0071320 cellular response to cAMP 5.672 0.002 0.372 
GO:0071371 cellular response to gonadotropin stimulus 6.947 0.002 0.372 
GO:0009435 NAD biosynthetic process 5.381 0.003 0.372 
GO:0043679 axon terminus 5.302 0.003 0.372 
GO:0048168 regulation of neuronal synaptic plasticity 4.912 0.003 0.372 
GO:0001102 
RNA polymerase II activating transcription factor 
binding 3.982 0.004 0.372 
GO:0006611 protein export from nucleus 4.843 0.004 0.372 
GO:0031105 septin complex 4.558 0.004 0.372 
GO:0033147 
negative regulation of intracellular estrogen 
receptor signaling pathway 5.834 0.004 0.372 
GO:0007611 learning or memory 4.332 0.005 0.372 
GO:0031625 ubiquitin protein ligase binding 2.748 0.005 0.372 
 
Table 4.6. Gene Ontology (GO) terms found by SCCA and GSEA method in Prostate Cancer data. We list 




Table 4.7. GO analysis by DAVID 
GO Term 
Fold 
Enrichment P-value Benjamini 
GO:0046907~intracellular transport 1.79 p<0.001 1.61E-08 
GO:0044451~nucleoplasm part 1.86 p<0.001 1.61E-08 
GO:0031981~nuclear lumen 1.48 p<0.001 1.09E-08 
GO:0016568~chromatin modification 2.16 p<0.001 9.94E-07 
GO:0005654~nucleoplasm 1.59 p<0.001 2.59E-07 
GO:0008104~protein localization 1.57 p<0.001 2.19E-06 
GO:0030163~protein catabolic process 1.70 p<0.001 1.69E-06 
GO:0044265~cellular macromolecule catabolic process 1.63 p<0.001 2.02E-06 
GO:0051603~proteolysis involved in cellular protein catabolic 
process 1.70 p<0.001 1.72E-06 
GO:0015031~protein transport 1.61 p<0.001 1.99E-06 
GO:0044257~cellular protein catabolic process 1.70 p<0.001 1.74E-06 
GO:0045184~establishment of protein localization 1.60 p<0.001 1.57E-06 
GO:0043632~modification-dependent macromolecule catabolic 
process 1.69 p<0.001 3.89E-06 
GO:0019941~modification-dependent protein catabolic process 1.69 p<0.001 3.89E-06 
GO:0005794~Golgi apparatus 1.56 p<0.001 1.58E-06 
GO:0009057~macromolecule catabolic process 1.58 p<0.001 3.72E-06 
GO:0070013~intracellular organelle lumen 1.36 p<0.001 1.45E-06 
GO:0070727~cellular macromolecule localization 1.82 p<0.001 6.64E-06 
GO:0000123~histone acetyltransferase complex 3.91 p<0.001 2.70E-06 
GO:0034613~cellular protein localization 1.81 p<0.001 9.07E-06 
 
Table 4.7. Gene Ontology (GO) found by DAVID online software in Prostate Cancer data. We analyzed 
predicted target gene list of 154 significant down regulated miRNAs by DAVID. The putative target list 




Table 4.8. GO analysis By DAVID  
Term Fold Enrichment P-value Benjamini 
GO:0004672~protein kinase activity 4.51 0.049 0.99 
GO:0006468~protein amino acid phosphorylation 4.27 0.06 1.00 
GO:0005624~membrane fraction 3.72 0.08 0.99 
GO:0043066~negative regulation of apoptosis 6.03 0.08 1.00 
GO:0043069~negative regulation of programmed cell death 5.95 0.08 1.00 
GO:0060548~negative regulation of cell death 5.93 0.08 1.00 
GO:0005626~insoluble fraction 3.58 0.08 0.94 
GO:0016310~phosphorylation 3.56 0.09 1.00 
GO:0005643~nuclear pore 19.03 0.09 0.88 
GO:0032553~ribonucleotide binding 2.23 0.10 0.99 
GO:0032555~purine ribonucleotide binding 2.23 0.10 0.99 
 
Table 4.8. Gene Ontology (GO) found by DAVID online software in Prostate Cancer data. We analyzed 
intersection gene list of predicted target gene list and up-regulated mRNAs by DAVID. The intersection list 




Table 4.9. GO analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
GO:0008104~protein localization 2.58 p<0.001 0.002 
GO:0015031~protein transport 2.72 p<0.001 0.001 
GO:0045184~establishment of protein localization 2.69 p<0.001 0.001 
GO:0034613~cellular protein localization 3.02 p<0.001 0.036 
GO:0070727~cellular macromolecule localization 3.00 p<0.001 0.032 
GO:0046907~intracellular transport 2.42 p<0.001 0.05 
GO:0006886~intracellular protein transport 2.95 p<0.001 0.07 
GO:0046320~regulation of fatty acid oxidation 12.33 p<0.001 0.12 
GO:0005794~Golgi apparatus 2.06 p<0.001 0.22 
GO:0006605~protein targeting 3.53 0.001 0.18 
GO:0051028~mRNA transport 5.55 0.002 0.22 
GO:0051236~establishment of RNA localization 4.98 0.003 0.33 
GO:0050658~RNA transport 4.98 0.003 0.33 
GO:0050657~nucleic acid transport 4.98 0.003 0.33 
GO:0006403~RNA localization 4.83 0.003 0.34 
GO:0050872~white fat cell differentiation 29.58 0.004 0.39 
GO:0031981~nuclear lumen 1.63 0.005 0.49 
GO:0019217~regulation of fatty acid metabolic process 7.04 0.005 0.45 
GO:0015931~nucleobase, nucleoside, nucleotide and 
nucleic acid transport 4.28 0.006 0.46 
GO:0000398~nuclear mRNA splicing, via spliceosome 3.61 0.007 0.48 
 
Table 4.9. Gene Ontology (GO) found by DAVID online software in Prostate Cancer data. We analysed 
intersection gene list of predicted target gene list and mRNAs found by pair wise correlation method of 154 
significant down regulated miRNAs by DAVID. The intersection list contained 256 genes and we list first 




After we analyzed the 8,934 probes from the Hu35KsubA chip, we did a similar analysis on the 7,129 probes 
in the Hu6800 microarrays. 
After filtering 7,129 probes in Hu6800 microarrays with function nsFilter within R package genefilter, we 
had 2,643 probes left. Then, we used same procedures with Hu35KsubA chip analysis to determined three 
lists of targets mRNAs. The first list consisted of 2,234 putative target genes of the DE miRNAs. The second 
list consisted of 23 intersected genes between putative targets and the 68 up regulated DE genes. The third 
list was based on 233 overlapped genes between putative target mRNAs of miRNAs and mRNAs that had 
significant inverse correlation with the differentially expressed miRNAs.  
After getting the three lists, we applied the SCCA method based on the 154 significant down-regulated 
miRNAs data and all the 2,643 filtered mRNAs from the Hu6800 chip. In the result, only the first set of 
canonical variables had significant p-value, so, with the first set canonical variables there were 49 non-zero 
elements in the 𝒖 vector, which meant that 49 mRNAs were selected by the SCCA function. And there were 
2 non-zero elements in 𝒗 vector, which indicated 2 miRNAs were selected. 
The next step was KEGG pathway analysis with the SCCA- GSEA method. The pathways are given in Table 




Table 4.10. KEGG pathway analysis by First canonical vector and Self-contained test 
KEGG ID Pathway Statisitc P-value Adj.P-value 
565 Ether lipid metabolism 4.359 0.01 0.581 
592 alpha-Linolenic acid metabolism 2.757 0.01 0.581 
3010 Ribosome 2.774 0.01 0.581 
3008 Ribosome biogenesis in eukaryotes 3.35 0.01 0.709 
4950 Maturity onset diabetes of the young 3.289 0.02 0.763 
3013 RNA transport 2.883 0.02 0.763 
3022 Basal transcription factors 3.121 0.03 0.790 
4150 mTOR signaling pathway 1.613 0.03 0.790 
 
Table 4.10. KEGG pathway found by SCCA and GSEA method in the Prostate Cancer data with Hu68000 




Table 4.11. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
hsa05200:Pathways in cancer 1.84 p<0.001 p<0.001 
hsa04510:Focal adhesion 2.07 p<0.001 p<0.001 
hsa04020:Calcium signaling pathway 2.07 p<0.001 p<0.001 
hsa04010:MAPK signaling pathway 1.84 p<0.001 p<0.001 
hsa04722:Neurotrophin signaling pathway 2.11 p<0.001 p<0.001 
hsa04012:ErbB signaling pathway 2.23 p<0.001 p<0.001 
hsa04910:Insulin signaling pathway 1.90 p<0.001 p<0.001 
hsa04350:TGF-beta signaling pathway 2.16 p<0.001 p<0.001 
hsa04810:Regulation of actin cytoskeleton 1.67 p<0.001 p<0.001 
hsa05215:Prostate cancer 2.11 p<0.001 p<0.001 
hsa05211:Renal cell carcinoma 2.28 p<0.001 p<0.001 
hsa04620:Toll-like receptor signaling pathway 2.03 p<0.001 p<0.001 
hsa04720:Long-term potentiation 2.26 p<0.001 p<0.001 
hsa04512:ECM-receptor interaction 2.10 p<0.001 p<0.001 
hsa04070:Phosphatidylinositol signaling system 2.16 p<0.001 p<0.001 
hsa05214:Glioma 2.26 p<0.001 p<0.001 
hsa04660:T cell receptor signaling pathway 1.90 p<0.001 p<0.001 
hsa05216:Thyroid cancer 2.95 p<0.001 p<0.001 
hsa04730:Long-term depression 2.15 p<0.001 p<0.001 
hsa05221:Acute myeloid leukemia 2.26 p<0.001 p<0.001 
 
Table 4.11. KEGG pathway found by DAVID online software in Prostate Cancer data with Hu68000 chip. 
We analyzed predicted target gene list of 154 significant down regulated miRNAs by DAVID. The putative 




Table 4.12. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-Value Benjamini 
hsa04020:Calcium signaling pathway 27.94 0.06 0.74 
 
Table 4.12. KEGG pathway found by DAVID online software in Prostate Cancer data with Hu68000 chip. 
We analyzed intersection gene list of predicted target gene list and up-regulated mRNAs by DAVID. The 
intersection list contained 23 genes. There was only one pathway discovered. 
 
 
Table 4.13. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-Value Benjamini 
hsa04020:Calcium signaling pathway 2.74 0.016 0.84 
hsa05412:Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 3.52 0.05 0.95 
hsa04142:Lysosome 2.74 0.06 0.93 
hsa04722:Neurotrophin signaling pathway 2.59 0.08 0.91 
hsa05010:Alzheimer's disease 2.30 0.08 0.86 
hsa05215:Prostate cancer 3.01 0.08 0.81 
 
Table 4.13. KEGG pathway found by DAVID online software in Prostate Cancer data with Hu68000 chip. 
We analyzed intersection gene list of predicted target gene list and mRNAs found by pair wise correlation 
method of 154 down regulated miRNAs by DAVID. The intersection list contained 233 genes and there were 




After KEGG pathway analysis, we did a similar analysis on GO terms based on the Hu6800 microarrays. 
FDR adjusted p-values from these pathways are given in Table 4.14. For comparison purposes, the results 
from DAVID analysis of the GO database with default parameters are given in Tables 4.15- 4.17 for all 
putative targets, all putative targets intersected with significantly up-regulated mRNAs, and all putative 




Table 4.14. GO pathway analysis by First canonical vector and Self-contained test 
GO ID GO Term Statisitc P-value Adj.P-value 
GO:0002039 p53 binding 5.729 p<0.001 p<0.001 
GO:0006413 translational initiation 4.969 p<0.001 p<0.001 
GO:0019003 GDP binding 6.519 p<0.001 0.156 
GO:0019068 virion assembly 9.036 p<0.001 0.156 
GO:0019082 viral protein processing 9.036 p<0.001 0.156 
GO:0044267 cellular protein metabolic process 4.183 p<0.001 0.156 
GO:0044822 poly(A) RNA binding 4.151 p<0.001 0.175 
GO:0071236 cellular response to antibiotic 8.104 p<0.001 0.175 
GO:0075733 intracellular transport of virus 8.322 p<0.001 0.260 
GO:0006184 GTP catabolic process 4.825 0.001 0.421 
GO:0015031 protein transport 4.764 0.001 0.484 
GO:0031901 early endosome membrane 5.105 0.001 0.484 
GO:0016197 endosomal transport 5.341 0.002 0.484 
GO:0019058 viral life cycle 4.623 0.002 0.484 
GO:0030914 STAGA complex 8.003 0.002 0.484 
GO:0047497 mitochondrion transport along microtubule 7.709 0.002 0.484 
GO:0060675 ureteric bud morphogenesis 9.23 0.002 0.484 
GO:0060760 
positive regulation of response to cytokine 
stimulus 8.131 0.002 0.484 
GO:1900103 
 positive regulation of endoplasmic reticulum 
unfolded protein response 8.551 0.002 0.484 
GO:0000139 Golgi membrane 3.636 0.003 0.484 
 
Table 4.14. Gene Ontology (GO) found by SCCA and GSEA method in Prostate Cancer data with Hu68000 




Table 4.15. GO analysis by DAVID 
GO Term Fold Enrichment P-Value Benjamini 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 2.14 p<0.001 p<0.001 
GO:0044459~plasma membrane part 1.59 p<0.001 p<0.001 
GO:0010033~response to organic substance 2.08 p<0.001 p<0.001 
GO:0010604~positive regulation of macromolecule 
metabolic process 1.95 p<0.001 p<0.001 
GO:0051173~positive regulation of nitrogen compound 
metabolic process 2.06 p<0.001 p<0.001 
GO:0045935~positive regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process 2.08 p<0.001 p<0.001 
GO:0010557~positive regulation of macromolecule 
biosynthetic process 2.04 p<0.001 p<0.001 
GO:0042127~regulation of cell proliferation 1.93 p<0.001 p<0.001 
GO:0006793~phosphorus metabolic process 1.82 p<0.001 p<0.001 
GO:0006796~phosphate metabolic process 1.82 p<0.001 p<0.001 
GO:0009891~positive regulation of biosynthetic process 1.99 p<0.001 p<0.001 
GO:0031328~positive regulation of cellular biosynthetic 
process 1.99 p<0.001 p<0.001 
GO:0051254~positive regulation of RNA metabolic process 2.19 p<0.001 p<0.001 
GO:0007242~intracellular signaling cascade 1.67 p<0.001 p<0.001 
GO:0045941~positive regulation of transcription 2.08 p<0.001 p<0.001 
GO:0010628~positive regulation of gene expression 2.06 p<0.001 p<0.001 
GO:0045893~positive regulation of transcription, DNA-
dependent 2.18 p<0.001 p<0.001 
GO:0045944~positive regulation of transcription from RNA 
polymerase II promoter 2.36 p<0.001 p<0.001 
GO:0007167~enzyme linked receptor protein signaling 
pathway 2.40 p<0.001 p<0.001 
GO:0030528~transcription regulator activity 1.57 p<0.001 p<0.001 
 
Table 4.15. Gene Ontology (GO) found by DAVID online software in Prostate Cancer data with Hu68000 
chip. We analyzed predicted target gene list of 154 significant down regulated miRNAs by DAVID. The 




Table 4.16. GO analysis by DAVID 
Term Fold Enrichment P-Value Benjamini 
GO:0030554~adenyl nucleotide binding 3.29 0.005 0.47 
GO:0001883~purine nucleoside binding 3.24 0.006 0.29 
GO:0001882~nucleoside binding 3.22 0.006 0.21 
GO:0000166~nucleotide binding 2.60 0.010 0.26 
GO:0055117~regulation of cardiac muscle contraction 147.04 0.013 1.00 
GO:0017076~purine nucleotide binding 2.71 0.015 0.31 
GO:0005524~ATP binding 3.08 0.016 0.28 
GO:0032559~adenyl ribonucleotide binding 3.04 0.017 0.26 
GO:0006793~phosphorus metabolic process 3.63 0.018 0.99 
GO:0006796~phosphate metabolic process 3.63 0.018 0.99 
GO:0051173~positive regulation of nitrogen compound 
metabolic process 
4.57 0.019 0.95 
GO:0006809~nitric oxide biosynthetic process 98.03 0.019 0.90 
GO:0046209~nitric oxide metabolic process 90.49 0.021 0.87 
GO:0031328~positive regulation of cellular biosynthetic 
process 
4.29 0.023 0.84 
GO:0009891~positive regulation of biosynthetic process 4.23 0.024 0.81 
GO:0045429~positive regulation of nitric oxide biosynthetic 
process 
56.02 0.034 0.87 
GO:0006942~regulation of striated muscle contraction 53.47 0.035 0.85 
GO:0016310~phosphorylation 3.68 0.038 0.84 
GO:0032555~purine ribonucleotide binding 2.47 0.042 0.48 
GO:0032553~ribonucleotide binding 2.47 0.042 0.48 
 
Table 4.16. Gene Ontology (GO) found by DAVID online software in Prostate Cancer data with Hu68000 
chip. We analyzed intersection gene list of predicted target gene list and up-regulated mRNAs by DAVID. 




Table 4.17. GO analysis by DAVID 
Term Fold Enrichment P-Value Benjamini 
GO:0010033~response to organic substance 2.78 p<0.001 p<0.001 
GO:0043566~structure-specific DNA binding 6.18 p<0.001 p<0.001 
GO:0005829~cytosol 2.30 p<0.001 p<0.001 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 2.67 p<0.001 0.001 
GO:0003690~double-stranded DNA binding 7.25 p<0.001 0.001 
GO:0051173~positive regulation of nitrogen compound 
metabolic process 2.72 p<0.001 0.003 
GO:0045944~positive regulation of transcription from RNA 
polymerase II promoter 3.38 p<0.001 0.004 
GO:0042493~response to drug 4.35 p<0.001 0.004 
GO:0031328~positive regulation of cellular biosynthetic 
process 2.56 p<0.001 0.004 
GO:0009891~positive regulation of biosynthetic process 2.52 p<0.001 0.004 
GO:0042802~identical protein binding 2.60 p<0.001 0.003 
GO:0045893~positive regulation of transcription, DNA-
dependent 2.89 p<0.001 0.006 
GO:0051254~positive regulation of RNA metabolic process 2.86 p<0.001 0.006 
GO:0010604~positive regulation of macromolecule 
metabolic process 2.27 p<0.001 0.007 
GO:0010557~positive regulation of macromolecule 
biosynthetic process 2.49 p<0.001 0.008 
GO:0045935~positive regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process 2.51 p<0.001 0.009 
GO:0048732~gland development 5.10 p<0.001 0.009 
GO:0045941~positive regulation of transcription 2.55 p<0.001 0.013 
GO:0016564~transcription repressor activity 3.24 p<0.001 0.015 
GO:0010628~positive regulation of gene expression 2.48 p<0.001 0.019 
 
Table 4.17. Gene Ontology (GO) found by DAVID online software in Prostate Cancer data with Hu68000 
chip. We analyzed intersection gene list of predicted target gene list and mRNAs found by pair wise 
correlation method of 154 significant down regulated miRNAs by DAVID. The intersection list contained 




4.2. Colon Cancer  
The miRNA and mRNA microarray data sets of human colon cancer and normal cell we used were obtained 
from the Broad Institute and downloaded from the database:  
(http://www.broadinstitute.org/cgi-bin/cancer/datasets.cgi) (Ting, et al., 2005) 
The original data set contained seven colon cancer tumor and four normal human tissues for both miRNA 
and mRNA expression data. The miRNA data was filtered by minimum value 32 and log2 transformed, so, 
the minimum value was 𝑙𝑜𝑔2(32) = 5. The mRNA data was obtained by using Affymetrix GENECHIP 
analysis software. There were 2 chips Hu35KsubA and Hu6800 in the data. The mRNA contained 16,063 
probes which was 8,934 and 7,129 probes respectively in each chip.  
The first part of the analysis was on the 8,934 Hu35KsubA probes. In the paper, we first filtered out the 18 
miRNAs which variances were 0, and there were 199 miRNAs left. Then, we applied the function nsFilter 
within R package genefilter on the mRNA data. After filtering, 2,917 features were left.  
Second, we determined significant down regulated differentially expressed miRNAs between tumor and 
normal samples. We first made a contrast comparing tumor to normal samples, second fitted the linear model 
to estimate the contrast by the lmFit function under the limma package, then used the empirical Bayes method 
to compute moderated t-statistics and the log-odds of differential expression. We identified 26 significant DE 
miRNAs with adjusted p-values of moderated t-statistics less than or equal to 0.05 with a log fold change 
less than zero. The 26 DE miRNAs were down regulated in the tumor tissue. 
Third, we determined three lists (similarly to the prostate cancer data in Section 4.1) of target mRNAs which 
we would use in the gene set enrichment analysis with DAVID. The first list was consisted of target mRNAs 
of differentially expressed miRNAs. At last, we got 1,354 overlapped putative targeting genes in the list. 
 
The second list consisted of the intersection of putative target mRNAs and up regulated differentially 
expressed genes in the tumor tissues. We determined up regulated differentially expressed mRNA using the 
similar procedures when we determined down regulated differentially expressed miRNAs. We identified 200 
57 
 
up regulated differentially expressed mRNAs. Then we discovered 36 overlapped genes between up regulated 
DE mRNAs and the list of putative gene targets.  
The third list was the overlapped genes between putative target mRNAs of miRNAs and the target mRNAs 
which had significant inverse correlation with the down-regulated miRNAs. We got 100 mRNAs with FDR 
adjusted p-value of pair wise correlation between miRNAs and mRNAs less or equal to 0.05. And all of these 
100 genes were contained in the putative target list.  
Third, we applied the SCCA method based on the 26 significantly down regulated miRNAs in tumor tissues. 
and the 2,963 filtered mRNA expression data from the Hu35KsubA chip. We first normalized both miRNA 
and mRNA data sets so that each miRNA/ mRNA expression vector had mean 0 and standard deviation 1, 
then multiplied the miRNA data by -1. In the SCCA procedure, we first used the function CCA.permute in 
package PMA(Witten, et al., 2009) to determine the optimal penalties to be used in the CCA function for 
obtaining multiple sets of canonical variables. In the result, only first set of canonical variables had significant 
permuted p-values, so, penalties of 0.1 would be used for both mRNA and miRNA expression data. Then, 
we applied the CCA function with the mRNA and miRNA expression data. In the result, there were 390 non-
zero elements in u vector, which meant that 390 mRNAs were selected by the SCCA function. And there 
were 3 non-zero elements in the v vector, which indicated that 3 miRNAs were identified. 
The next step was KEGG pathway analysis with the SCCA- GSEA method. We first used the function 
GeneSetCollection within the R package GSEABase to construct a collection of gene sets from pathways in 
the KEGG database. There were 212 gene sets of pathways collected from KEGG. FDR adjusted p-values 
from these pathways are given in Table 4.18. For comparison, DAVID analysis of the KEGG database with 
default parameters based on the three gene lists we created are given in Tables 4.19- 4.21. The former is 
based on a 1,354 genes and identifies a large number of pathways. The middle is based on only 36 genes, 
and returns only two pathways. The latter contains only one KEGG pathway. Then, we produced a similar 
analysis based on GO terms. The result is in the Table 4.22 for the SCCA-GSEA method. The results of the 




Table 4.18. KEGG pathway analysis by First canonical vector and Self-contained test 
ENTREZID Pathway Statisitc P-value Adj.P-value 
512 Mucin type O-Glycan biosynthesis 3.96 p<0.001 p<0.001 
4614 Renin-angiotensin system 0.90 p<0.001 p<0.001 
5214 Glioma 3.02 0.00 0.03 
4310 Wnt signaling pathway 3.12 0.00 0.06 
4720 Long-term potentiation 4.13 0.00 0.09 
4740 Olfactory transduction 4.80 0.00 0.09 
4971 Gastric acid secretion 3.49 0.01 0.10 
4114 Oocyte meiosis 2.59 0.01 0.16 
4912 GnRH signaling pathway 2.53 0.01 0.18 
4012 ErbB signaling pathway 2.45 0.01 0.18 
4916 Melanogenesis 2.37 0.01 0.18 
4950 Maturity onset diabetes of the young 1.83 0.02 0.22 
3040 Spliceosome 2.07 0.02 0.24 
4722 Neurotrophin signaling pathway 2.00 0.02 0.28 
982 Drug metabolism - cytochrome P450 0.99 0.03 0.34 
4020 Calcium signaling pathway 2.02 0.03 0.34 
830 Retinol metabolism 0.87 0.04 0.35 
 
Table 4.18. KEGG pathway found by SCCA and GSEA method in Colon Cancer data. There were 18 




Table 4.19. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
hsa04144:Endocytosis 2.55 p<0.001 0.015 
hsa04910:Insulin signaling pathway 2.69 p<0.001 0.032 
hsa04330:Notch signaling pathway 4.09 p<0.001 0.06 
hsa04310:Wnt signaling pathway 2.41 p<0.001 0.05 
hsa04360:Axon guidance 2.48 p<0.001 0.07 
hsa04722:Neurotrophin signaling pathway 2.41 p<0.001 0.10 
hsa05210:Colorectal cancer 2.80 p<0.001 0.10 
hsa04930:Type II diabetes mellitus 3.64 p<0.001 0.09 
hsa04012:ErbB signaling pathway 2.70 p<0.001 0.10 
hsa04370:VEGF signaling pathway 2.85 p<0.001 0.10 
hsa05211:Renal cell carcinoma 2.75 p<0.001 0.17 
hsa04120:Ubiquitin mediated proteolysis 2.03 p<0.001 0.25 
hsa04520:Adherens junction 2.50 p<0.001 0.24 
hsa04660:T cell receptor signaling pathway 2.18 p<0.001 0.24 
hsa04666:Fc gamma R-mediated phagocytosis 2.25 p<0.001 0.26 
hsa05213:Endometrial cancer 2.88 p<0.001 0.25 
hsa04150:mTOR signaling pathway 2.88 p<0.001 0.25 
hsa04920:Adipocytokine signaling pathway 2.55 p<0.001 0.25 
hsa04720:Long-term potentiation 2.51 p<0.001 0.25 
hsa04115:p53 signaling pathway 2.51 p<0.001 0.25 
 
Table 4.19. KEGG pathway found by DAVID online software in Colon Cancer data. We analyzed predicted 
target gene list of 28 down regulated miRNAs by DAVID. The putative target list contained 1,354 genes. We 




Table 4.20. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
hsa04120:Ubiquitin mediated proteolysis 22.27 0.00 0.02 
hsa04330:Notch signaling pathway 43.28 0.04 0.07 
 
Table 4.20. KEGG pathway found by DAVID online software in Colon Cancer data. We analyzed 
intersection gene list of predicted target gene list and up-regulated mRNAs by DAVID. The intersection list 
contained 36 genes. There was only two pathway discovered. 
 
 
Table 4.21. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
hsa04120:Ubiquitin mediated proteolysis 5.57 0.09 0.89 
 
Table 4.21. KEGG pathway found by DAVID online software in Colon Cancer data. We analyzed 
intersection gene list of predicted target gene list and mRNAs found by pair wise correlation method of 26 
down regulated miRNAs by DAVID. The intersection list contained 100 genes and there was only one 




Table 4.22. GO pathway analysis by First canonical vector and Self-contained test 
GO ID GO Term Statisitc P-Value Adj.P-value 
GO:0014733 regulation of skeletal muscle adaptation 6.79 p<0.001 0.33 
GO:0051924 regulation of calcium ion transport 8.31 p<0.001 0.33 
GO:0090129 positive regulation of synapse maturation 8.31 p<0.001 0.33 
GO:0004683 calmodulin-dependent protein kinase activity 5.88 0.001 0.36 
GO:0007268 synaptic transmission 3.20 0.001 0.36 
GO:0007369 gastrulation 7.16 0.001 0.36 
GO:0010976 
positive regulation of neuron projection 
development 5.57 0.001 0.36 
GO:0033017 sarcoplasmic reticulum membrane 5.72 0.001 0.36 
GO:0048169 
regulation of long-term neuronal synaptic 
plasticity 6.67 0.001 0.36 
GO:0060333 interferon-gamma-mediated signaling pathway 4.44 0.001 0.36 
GO:0060998 regulation of dendritic spine development 8.08 0.001 0.36 
GO:2001235 
positive regulation of apoptotic signaling 
pathway 4.80 0.001 0.36 
GO:0050885 neuromuscular process controlling balance 3.91 0.002 0.38 
GO:0051233 spindle midzone 4.54 0.002 0.41 
GO:0030666 endocytic vesicle membrane 3.93 0.003 0.41 
GO:0046686 response to cadmium ion 4.40 0.003 0.41 
GO:0072383 
plus-end-directed vesicle transport along 
microtubule 5.96 0.003 0.41 
GO:0005815 microtubule organizing center 2.94 0.005 0.41 
GO:0006606 protein import into nucleus 4.00 0.005 0.41 
GO:0008333 endosome to lysosome transport 4.05 0.005 0.41 
 
Table 4.22. Gene Ontology (GO) found by SCCA and GSEA method in Colon Cancer data. We list first 20 




Table 4.23. GO analysis by DAVID 
GO Term Fold Enrichment P-value Benjamini 
GO:0031981~nuclear lumen 1.56 p<0.001 p<0.001 
GO:0016564~transcription repressor activity 2.27 p<0.001 0.004 
GO:0044451~nucleoplasm part 1.94 p<0.001 0.001 
GO:0019898~extrinsic to membrane 1.97 p<0.001 0.002 
GO:0016568~chromatin modification 2.28 p<0.001 0.053 
GO:0005654~nucleoplasm 1.66 p<0.001 0.003 
GO:0005768~endosome 2.19 p<0.001 0.003 
GO:0046907~intracellular transport 1.73 p<0.001 0.052 
GO:0006325~chromatin organization 2.00 p<0.001 0.041 
GO:0010629~negative regulation of gene expression 1.84 p<0.001 0.034 
GO:0012505~endomembrane system 1.66 p<0.001 0.005 
GO:0000123~histone acetyltransferase complex 4.47 p<0.001 0.009 
GO:0043005~neuron projection 2.02 p<0.001 0.010 
GO:0019941~modification-dependent protein catabolic 
process 1.71 p<0.001 0.09 
GO:0043632~modification-dependent macromolecule 
catabolic process 1.71 p<0.001 0.09 
GO:0016481~negative regulation of transcription 1.81 p<0.001 0.08 
GO:0045184~establishment of protein localization 1.60 p<0.001 0.07 
GO:0008104~protein localization 1.54 p<0.001 0.07 
GO:0016570~histone modification 2.79 p<0.001 0.06 
GO:0008536~Ran GTPase binding 9.45 p<0.001 0.09 
 
Table 4.23. Gene Ontology (GO) found by DAVID online software in Colon Cancer data. We analyzed 
predicted target gene list of 28 down regulated miRNAs by DAVID. The putative target list contained 1,354 




Table 4.24. GO analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
GO:0008270~zinc ion binding 2.289 0.010 0.581 
GO:0016570~histone modification 15.841 0.014 0.990 
GO:0016569~covalent chromatin modification 15.338 0.015 0.912 
GO:0030900~forebrain development 12.714 0.021 0.902 
GO:0030901~midbrain development 80.524 0.023 0.858 
GO:0046914~transition metal ion binding 1.899 0.036 0.785 
GO:0045665~negative regulation of neuron 
differentiation 39.042 0.048 0.960 
GO:0019941~modification-dependent protein catabolic 
process 4.489 0.051 0.943 
GO:0043632~modification-dependent macromolecule 
catabolic process 4.489 0.051 0.943 
GO:0017015~regulation of transforming growth factor 
beta receptor signaling pathway 33.035 0.056 0.934 
GO:0051603~proteolysis involved in cellular protein 
catabolic process 4.295 0.056 0.909 
GO:0044257~cellular protein catabolic process 4.273 0.057 0.884 
GO:0000122~negative regulation of transcription from 
RNA polymerase II promoter 7.265 0.058 0.861 
GO:0048663~neuron fate commitment 30.676 0.060 0.845 
GO:0016568~chromatin modification 7.053 0.061 0.824 
GO:0030163~protein catabolic process 4.143 0.062 0.801 
GO:0000123~histone acetyltransferase complex 26.909 0.068 0.999 
GO:0016573~histone acetylation 26.841 0.069 0.813 
GO:0031625~ubiquitin protein ligase binding 26.714 0.070 0.865 
GO:0046907~intracellular transport 3.922 0.070 0.799 
 
Table 4.24. Gene Ontology (GO) found by DAVID online software in Colon Cancer data. We analyzed 
intersection gene list of predicted target gene list and up-regulated mRNAs by DAVID. We list first 20 of 27 




Table 4.25. GO analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
GO:0000123~histone acetyltransferase complex 16.493 0.002 0.252 
GO:0016573~histone acetylation 15.657 0.002 0.806 
GO:0006473~protein amino acid acetylation 14.453 0.003 0.644 
GO:0008134~transcription factor binding 3.330 0.003 0.427 
GO:0043543~protein amino acid acylation 12.526 0.004 0.644 
GO:0016570~histone modification 7.700 0.004 0.541 
GO:0016569~covalent chromatin modification 7.456 0.004 0.503 
GO:0043966~histone H3 acetylation 21.679 0.008 0.668 
GO:0016568~chromatin modification 4.114 0.014 0.814 
GO:0008015~blood circulation 5.051 0.016 0.813 
GO:0003013~circulatory system process 5.051 0.016 0.813 
GO:0003712~transcription cofactor activity 3.294 0.018 0.851 
GO:0004468~lysine N-acetyltransferase activity 13.486 0.020 0.754 
GO:0004402~histone acetyltransferase activity 13.486 0.020 0.754 
GO:0015672~monovalent inorganic cation transport 3.545 0.026 0.903 
GO:0060177~regulation of angiotensin metabolic process 75.156 0.026 0.881 
GO:0002002~regulation of angiotensin levels in blood 75.156 0.026 0.881 
GO:0007507~heart development 4.370 0.026 0.860 
GO:0006605~protein targeting 4.370 0.026 0.860 
GO:0030695~GTPase regulator activity 2.960 0.029 0.781 
 
Table 4.25. Gene Ontology (GO) found by DAVID online software in Colon Cancer data. We analyzed 
intersection gene list of predicted target gene list and mRNAs found by pair wise correlation method of 26 
down regulated miRNAs by DAVID. The intersection list contained 100 genes and we list first 20 of 65 GO 




The next step was the analysis of the 7,071 probes in the Hu6800 microarrays, the process being identical to 
the analysis of the Hu35KsubA chip data. First, we identified 26 significant miRNAs with adjusted p-values 
of moderated t-statistics less than or equal to 0.05 and with a log 2 fold change less than 0, which meant all 
the DE miRNAs were down regulated in colon tumor tissue relative to normal tissue.  
Then, we determined three gene lists (as with the Hu35KsubA chip) of target mRNAs which we would use 
in the later analysis with DAVID. The first list contained 974 genes, the second list consisted of 36 genes 
and there were 53 genes in the third list. 
After getting the three lists, we used the SCCA method based on the data from the 26 significantly down 
regulated miRNAs and all the 2,643 filtered mRNA expression data from the Hu6800 chip. We first ran the 
CCA function with gene expressed data. We obtained the u and v vectors from the CCA function by the 
SCCA method, where the u vector with length 2643 was the canonical vector for mRNA expressed data and 
v with length 23 was the canonical vector of miRNA data. In the result, there were 950 non-zero elements in 
u vector, which meant that 950 mRNAs were selected by the SCCA function. And 13 non-zero elements in 
v vector, which indicated 13 miRNAs were selected. 
The next step was KEGG pathway analysis with the gene set enrichment analysis method.  The last step of 
GSEA was to calculate the permutation p-value of overall statistic for each pathway. The result is in Table 
4.26. The results of the DAVID analysis of the three gene lists are in Tables 4.27- 4.29. Then, we conducted 
a similar analysis based on GO terms. The result is in Table 4.30 for the SCCA-GSEA method. The results 




Table 4.26. KEGGpathway analysis by First canonical vector and Self-contained test 
ENTREZID Pathway Statisitc P-value Adj.P-value 
30 Pentose phosphate pathway 2.327 p< 0.001 p< 0.001 
270 Cysteine and methionine metabolism 2.274 p< 0.002 p< 0.002 
450 Selenocompound metabolism 0.000 p< 0.003 p< 0.003 
512 Mucin type O-Glycan biosynthesis 0.000 p< 0.004 p< 0.004 
760 Nicotinate and nicotinamide metabolism 1.400 p< 0.005 p< 0.005 
3018 RNA degradation 1.697 p< 0.006 p< 0.006 
3040 Spliceosome 4.017 p< 0.007 p< 0.007 
3050 Proteasome 1.965 p< 0.008 p< 0.008 
3450 Non-homologous end-joining 0.631 p< 0.009 p< 0.009 
970 Aminoacyl-tRNA biosynthesis 2.637 0.001 0.020 
3010 Ribosome 2.738 0.001 0.020 
310 Lysine degradation 1.168 0.003 0.050 
1040 Biosynthesis of unsaturated fatty acids 1.501 0.003 0.050 
480 Glutathione metabolism 1.531 0.009 0.139 
740 Riboflavin metabolism 1.108 0.011 0.158 
250 Alanine, aspartate and glutamate metabolism 1.987 0.015 0.203 
4512 ECM-receptor interaction 1.437 0.016 0.203 
10 Glycolysis / Gluconeogenesis 1.228 0.025 0.300 
1100 Metabolic pathways 0.962 0.034 0.387 
3013 RNA transport 2.317 0.039 0.413 
 
Table 4.26. KEGG pathway found by SCCA and GSEA method in Colon Cancer data with Hu6800 chip. 




Table 4.27. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
hsa04010:MAPK signaling pathway 2.16 p<0.001 p<0.001 
hsa05014:Amyotrophic lateral sclerosis (ALS) 4.15 p<0.001 p<0.001 
hsa04510:Focal adhesion 2.32 p<0.001 p<0.001 
hsa04012:ErbB signaling pathway 3.16 p<0.001 p<0.001 
hsa04720:Long-term potentiation 3.44 p<0.001 p<0.001 
hsa05410:Hypertrophic cardiomyopathy (HCM) 3.07 p<0.001 p<0.001 
hsa05200:Pathways in cancer 1.89 p<0.001 p<0.001 
hsa04350:TGF-beta signaling pathway 2.84 p<0.001 0.003 
hsa05216:Thyroid cancer 4.74 p<0.001 0.003 
hsa05412:Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 
2.89 p<0.001 0.005 
hsa04360:Axon guidance 2.34 p<0.001 0.005 
hsa04930:Type II diabetes mellitus 3.51 p<0.001 0.006 
hsa04310:Wnt signaling pathway 2.18 p<0.001 0.006 
hsa04910:Insulin signaling pathway 2.24 p<0.001 0.007 
hsa05414:Dilated cardiomyopathy 2.54 p<0.001 0.009 
hsa04114:Oocyte meiosis 2.37 p<0.001 0.008 
hsa04512:ECM-receptor interaction 2.62 p<0.001 0.009 
hsa05210:Colorectal cancer 2.62 p<0.001 0.009 
hsa05213:Endometrial cancer 3.17 p<0.001 0.009 
hsa04722:Neurotrophin signaling pathway 2.22 p<0.001 0.012 
 
Table 4.27. KEGG pathway found by DAVID online software in Colon Cancer data with Hu6800 chip. We 
analyzed predicted target gene list of 28 down regulated miRNAs by DAVID. The putative target list 




Table 4.28. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
hsa04510:Focal adhesion 9.90 p<0.001 p<0.001 
hsa04512:ECM-receptor interaction 15.79 p<0.001 p<0.001 
hsa04810:Regulation of actin cytoskeleton 4.11 0.06 0.61 
 
Table 4.28. KEGG pathway found by DAVID online software in Colon Cancer data with Hu6800 chip. We 
analyzed list 2 by DAVID. The gene list contained 36 genes, and three KEGG pathway were found. 
 
 
Table 4.29. KEGG pathway analysis by DAVID 
Term Fold Enrichment P-value Benjamini 
hsa04510:Focal adhesion 7.85 p< 0.001 p< 0.001 
hsa04512:ECM-receptor interaction 12.52 p< 0.001 0.003 
hsa04810:Regulation of actin cytoskeleton 4.08 0.029 0.49 
hsa05211:Renal cell carcinoma 7.51 0.06 0.64 
 
Table 4.29. KEGG pathway found by DAVID online software in Colon Cancer data with Hu6800 chip. We 
analyzed intersection gene list of predicted target gene list and mRNAs found by pair wise correlation method 
of 28 down regulated miRNAs by DAVID. The intersection list contained 53 genes and there was only one 




Table 4.30. GO pathway analysis by First canonical vector and Self-contained test 
GO ID GO Term Statisitc P-Value Adj.Pvalue 
GO:0000398 mRNA splicing, via spliceosome 4.154 p< 0.001 p< 0.001 
GO:0002199 zona pellucida receptor complex 4.119 p< 0.001 p< 0.001 
GO:0003697 single-stranded DNA binding 4.158 p< 0.001 p< 0.001 
GO:0003723 RNA binding 3.774 p< 0.001 p< 0.001 
GO:0005515 protein bindin 1.919 p< 0.001 p< 0.001 
GO:0005829 cytosol 2.690 p< 0.001 p< 0.001 
GO:0005832 chaperonin-containing T-complex 4.404 p< 0.001 p< 0.001 
GO:0006457 protein folding 3.148 p< 0.001 p< 0.001 
GO:0007339 binding of sperm to zona pellucida 3.884 p< 0.001 p< 0.001 
GO:0007599 hemostasis 4.536 p< 0.001 p< 0.001 
GO:0008380 RNA splicing 4.492 p< 0.001 0.029 
GO:0009566 fertilization 4.121 p< 0.001 0.029 
GO:0010467 gene expression 4.211 p< 0.001 0.029 
GO:0010899 
regulation of phosphatidylcholine catabolic 
process 4.385 p< 0.001 0.029 
GO:0016032 viral process 3.575 p< 0.001 0.029 
GO:0016070 RNA metabolic process 3.625 p< 0.001 0.029 
GO:0016192 vesicle-mediated transport 3.804 p< 0.001 0.049 
GO:0030529 ribonucleoprotein complex 3.537 p< 0.001 0.049 
GO:0044822 poly(A) RNA binding 6.577 p< 0.001 0.049 
GO:0051082 unfolded protein binding 4.811 p< 0.001 0.070 
 
Table 4.30. Gene Ontology (GO) found by SCCA and GSEA method in Colon Cancer data with Hu6800 




Table 4.31. GO analysis by DAVID 
GO Term Fold Enrichment P-Value Benjamini 
GO:0044459~plasma membrane part 1.64 p< 0.001 p< 0.001 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 
2.17 p< 0.001 p< 0.001 
GO:0030528~transcription regulator activity 1.68 p< 0.001 p< 0.001 
GO:0019226~transmission of nerve impulse 2.61 p< 0.001 p< 0.001 
GO:0006796~phosphate metabolic process 1.86 p< 0.001 p< 0.001 
GO:0006793~phosphorus metabolic process 1.86 p< 0.001 p< 0.001 
GO:0005829~cytosol 1.74 p< 0.001 p< 0.001 
GO:0007517~muscle organ development 3.15 p< 0.001 p< 0.001 
GO:0007267~cell-cell signaling 2.12 p< 0.001 p< 0.001 
GO:0007507~heart development 3.09 p< 0.001 p< 0.001 
GO:0007167~enzyme linked receptor protein signaling 
pathway 
2.57 p< 0.001 p< 0.001 
GO:0046907~intracellular transport 2.05 p< 0.001 p< 0.001 
GO:0045202~synapse 2.60 p< 0.001 p< 0.001 
GO:0007268~synaptic transmission 2.65 p< 0.001 p< 0.001 
GO:0044057~regulation of system process 2.61 p< 0.001 p< 0.001 
GO:0051173~positive regulation of nitrogen compound 
metabolic process 
2.03 p< 0.001 p< 0.001 
GO:0005516~calmodulin binding 3.63 p< 0.001 p< 0.001 
GO:0048878~chemical homeostasis 2.17 p< 0.001 p< 0.001 
GO:0060537~muscle tissue development 3.73 p< 0.001 p< 0.001 
GO:0005667~transcription factor complex 3.08 p< 0.001 p< 0.001 
 
Table 4.31. Gene Ontology (GO) found by DAVID online software in Colon Cancer data with Hu6800. We 
analyzed predicted target gene list of 26 down regulated miRNAs by DAVID. The putative target list 




Table 4.32. GO analysis by DAVID 
Term Fold Enrichment P-Value Benjamini 
GO:0044420~extracellular matrix part 21.14 p< 0.001 0.001 
GO:0005578~proteinaceous extracellular matrix 9.02 p< 0.001 0.005 
GO:0031012~extracellular matrix 8.37 p< 0.001 0.005 
GO:0005201~extracellular matrix structural constituent 18.30 0.001 0.14 
GO:0007155~cell adhesion 4.55 0.001 0.49 
GO:0022610~biological adhesion 4.54 0.001 0.29 
GO:0030198~extracellular matrix organization 15.30 0.002 0.31 
GO:0030199~collagen fibril organization 41.16 0.002 0.26 
GO:0005581~collagen 35.34 0.003 0.09 
GO:0044421~extracellular region part 3.44 0.006 0.14 
GO:0043062~extracellular structure organization 9.76 0.007 0.54 
GO:0032964~collagen biosynthetic process 159.15 0.012 0.67 
GO:0007015~actin filament organization 16.58 0.013 0.64 
GO:0046164~alcohol catabolic process 14.74 0.017 0.68 
GO:0030036~actin cytoskeleton organization 7.04 0.017 0.65 
GO:0005198~structural molecule activity 3.72 0.018 0.67 
GO:0007160~cell-matrix adhesion 13.41 0.020 0.66 
GO:0030029~actin filament-based process 6.60 0.021 0.64 
GO:0007010~cytoskeleton organization 4.56 0.021 0.61 
GO:0030674~protein binding, bridging 12.56 0.022 0.60 
 
Table 4.32. Gene Ontology (GO) found by DAVID online software in Colon Cancer data with Hu6800 chip. 
We analyzed intersection gene list of predicted target gene list and up-regulated mRNAs of 26 down 





Table 4.33. GO analysis by DAVID 
Term Fold Enrichment P-Value Benjamini 
GO:0044420~extracellular matrix part 15.24 p< 0.001 0.006 
GO:0005581~collagen 33.97 p< 0.001 0.015 
GO:0005578~proteinaceous extracellular matrix 6.50 0.001 0.029 
GO:0031012~extracellular matrix 6.03 0.001 0.032 
GO:0007155~cell adhesion 3.55 0.003 0.87 
GO:0022610~biological adhesion 3.54 0.003 0.65 
GO:0005201~extracellular matrix structural constituent 13.42 0.003 0.35 
GO:0007264~small GTPase mediated signal transduction 5.43 0.004 0.64 
GO:0030199~collagen fibril organization 28.56 0.005 0.56 
GO:0030198~extracellular matrix organization 10.62 0.006 0.56 
GO:0016071~mRNA metabolic process 4.48 0.010 0.68 
GO:0003697~single-stranded DNA binding 15.74 0.015 0.66 
GO:0005178~integrin binding 14.67 0.017 0.56 
GO:0032964~collagen biosynthetic process 110.43 0.018 0.83 
GO:0043062~extracellular structure organization 6.78 0.020 0.83 
GO:0016564~transcription repressor activity 4.57 0.022 0.54 
GO:0005829~cytosol 2.24 0.026 0.56 
GO:0006397~mRNA processing 4.30 0.027 0.88 
GO:0007015~actin filament organization 11.50 0.027 0.85 
GO:0008544~epidermis development 6.00 0.027 0.83 
 
Table 4.33. Gene Ontology (GO) found by DAVID online software in Colon Cancer data with Hu6800. We 
analyzed intersection gene list of predicted target gene list and mRNAs found by pair wise correlation method 
of 26 down regulated miRNAs by DAVID. The intersection list contained 53 genes and we list first 20 GO 




4.3 Birth Defects Center, Dental school neural tube data 
The miRNA and mRNA microarray data sets from the murine embryonic neural tube (NT) development 
study contained four 8.5- NT- arrays, four 9.0-NT-arrays and four 9.5-NT- arrays for both miRNA and 
mRNA expression data. The data were collected at three gestational days (GD), 8.5, 9.0, and 9.5. The miRNA 
expression data was obtained by using AffyBatch analysis software and the annotation of the data was 
mirna20. The number of samples in the miRNA data was 12 and the number of miRNA genes was 20,706. 
The mRNA data totally contained 12 samples and 45,101 features. The mRNA data was obtained by using 
Affymetrix GENECHIP analysis software. The annotation of the data was mouse4302.  
In the analysis, we first filtered the data set. For original miRNA data, there were 20,706 miRNAs and 12 
samples. We kept the miRNAs for which the name of genes started with “mmu-”. As the result of filtering, 
there were 1,412 genes left. In the mRNA expression data, we used the function affy::rma within R package 
pd.mirna.2.0 to filter the mRNA data by removing duplicate probes mapping to the same Entrez Gene ID 
(the probe with the highest variance across the samples was retained) and probes with a variance below the 
50th percentile. After filtering there were 10,336 probes remaining.  
Second, we determined differentially expressed miRNAs between 9.5- NT and 8.5- NT arrays using the 
empirical Bayes method in the R package limma (Ritchie, et al., 2015) (Smyth, 2004). We identified 183 
significant miRNAs with adjusted p-values (based on Benjamini-Hochberg correction) ≤ 0.05. 52 out of 183 
miRNAs with positive log fold change were up regulated on GD 9.5 relative to GD 8.5, and other 131 
miRNAs with negative log fold changes are down regulated. 
Third, we determined three lists of target mRNAs which we would use in the later analysis with DAVID. 
The first part was the result of 52 up regulated miRNAs. The first list consisted of putative target genes of 
the DE miRNAs, based on the intersection of targets in the miRBase (Kozomara and Griffiths-Jones, 2014) 
and TargetScan (Lewis, et al., 2003) databases. This resulted in 5,154 putative target genes of the up regulated 
miRNAs. The second list consisted of intersecting this putative target list with the up regulated DE genes. 
We determined up regulated DE genes using the same procedures as for the miRNAs. Here we identified 
3,037 down regulated and DE (adjusted p-value < 0.05) mRNAs. The intersection of this list with the list of 
putative target genes resulted in 530 total genes. The third list was the overlapped genes between putative 
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target mRNAs of miRNAs and significant genes obtained by pair wise correlation with differentially 
expressed miRNAs. Here we identified 456 mRNAs with significant negative correlation (adjusted p-value 
< 0.05) between miRNAs and mRNA. The intersection of this list with the list of putative target genes 
resulted in 424 total genes. 
After getting the three lists, we used the SCCA method based on the expression data of the 52 up-regulated 
miRNAs and all the 10,336 filtered mRNA expression data from the mouse4302 chip. After normalizing 
each of the matrices so that expression measurements for each miRNA / mRNA had mean zero and standard 
deviation one, the miRNA data was multiplied by -1. The CCA.permute function in package PMA (Witten, 
et al., 2009) was used to determine optimal penalty parameters for SCCA with multiple sets of canonical 
variables. In the result, there were 8,603 non-zero elements in the 𝒖 vector, which meant that 8,603 mRNAs 
were selected by the SCCA function. And there were 43 non-zero elements in 𝒗 vector, which indicated 43 
miRNAs were selected. 
The next step was KEGG pathway analysis with the SCCA GSEA method. We first used the 
GeneSetCollection function within the Bioconductor package GSEABase to construct a collection of gene 
sets of pathways from the KEGG database. There were 224 pathways collected from KEGG. FDR adjusted 
p-values from these pathways are given in Table 4.34. For comparison purposes, the results from DAVID 
analysis of the KEGG database with default parameters based on all 5,154 putative targets, the 416 
intersection of these targets with the 2,838 DE down regulated genes and the 424 intersection of putative 




Table 4.34. KEGG pathway analysis by Multiple canonical vectors and Self-contained test 
pathway Statistic P-value Adj.P-value 
Oxidative phosphorylation 2.065 p< 0.001 p< 0.001 
Glycine, serine and threonine metabolism 1.416 p< 0.001 p< 0.001 
Protein export 1.613 p< 0.001 p< 0.001 
Chemokine signaling pathway 1.825 p< 0.001 p< 0.001 
Lysosome 1.559 p< 0.001 p< 0.001 
Cardiac muscle contraction 2.406 p< 0.001 p< 0.001 
Natural killer cell mediated cytotoxicity 1.751 p< 0.001 p< 0.001 
Fc gamma R-mediated phagocytosis 2.148 p< 0.001 p< 0.001 
Leukocyte transendothelial migration 2.071 p< 0.001 p< 0.001 
Regulation of actin cytoskeleton 1.096 p< 0.001 p< 0.001 
Vitamin digestion and absorption 2.190 p< 0.001 p< 0.001 
Small cell lung cancer 1.975 p< 0.001 p< 0.001 
Rheumatoid arthritis 2.316 p< 0.001 p< 0.001 
Hypertrophic cardiomyopathy (HCM) 1.712 p< 0.001 p< 0.001 
Dilated cardiomyopathy 1.635 p< 0.001 p< 0.001 
Phagosome 2.601 0.001 0.012 
NOD-like receptor signaling pathway 1.053 0.001 0.012 
Bladder cancer 1.442 0.001 0.012 
Fc epsilon RI signaling pathway 1.369 0.002 0.023 
Collecting duct acid secretion 2.265 0.003 0.031 
 
Table 4.34. KEGG pathway found by SCCA and GSEA method in Neural Tube data. We list 20 of 48 KEGG 




Table 4.35 KEGG Pathway analysis of predicted targets of up regulated miRNAs 
Term Fold Enrichment P-value Benjamini 
mmu04360:Axon guidance 3.56 p<0.001 p<0.001 
mmu04010:MAPK signaling pathway 2.54 p<0.001 p<0.001 
mmu05200:Pathways in cancer 2.35 p<0.001 p<0.001 
mmu05210:Colorectal cancer 3.42 p<0.001 0.001 
mmu04910:Insulin signaling pathway 2.76 p<0.001 0.001 
mmu04810:Regulation of actin cytoskeleton 2.23 p<0.001 0.003 
mmu05221:Acute myeloid leukemia 3.64 p<0.001 0.008 
mmu04720:Long-term potentiation 3.21 0.001 0.011 
mmu04310:Wnt signaling pathway 2.32 0.001 0.015 
mmu04150:mTOR signaling pathway 3.52 0.001 0.014 
mmu04510:Focal adhesion 2.09 0.001 0.013 
mmu05211:Renal cell carcinoma 2.96 0.002 0.026 
mmu04660:T cell receptor signaling pathway 2.34 0.003 0.036 
mmu04722:Neurotrophin signaling pathway 2.26 0.003 0.034 
mmu04914:Progesterone-mediated oocyte maturation 2.64 0.003 0.034 
mmu05220:Chronic myeloid leukemia 2.73 0.004 0.038 
mmu04012:ErbB signaling pathway 2.58 0.004 0.036 
mmu04916:Melanogenesis 2.42 0.005 0.040 
mmu05215:Prostate cancer 2.50 0.005 0.042 
mmu04730:Long-term depression 2.64 0.008 0.060 
 
Table 4.35. KEGG pathway found by DAVID online software in Neural Tube data. We analyzed predicted 
target gene list of 52 up regulated miRNAs by DAVID. The putative target list contained 5,154 genes. We 




Table 4.36 KEGG Pathway analysis of mRNAs from intersection of different data base of up regulated 
miRNAs 
Term Fold Enrichment P-value Benjamini 
mmu00600:Sphingolipid metabolism 6.83 p<0.001 0.06 
mmu04144:Endocytosis 2.64 0.003 0.19 
mmu05412:Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
3.83 0.009 0.32 
mmu05200:Pathways in cancer 2.03 0.011 0.29 
mmu04960:Aldosterone-regulated sodium reabsorption 4.88 0.018 0.36 
mmu04142:Lysosome 2.76 0.025 0.41 
mmu04666:Fc gamma R-mediated phagocytosis 2.51 0.09 0.81 
mmu00071:Fatty acid metabolism 3.64 0.09 0.79 
 
Table 4.36. KEGG pathway found by DAVID online software in Neural Tube data. We analyzed intersection 
gene list of predicted target gene list and down-regulated mRNAs by DAVID. The intersection list contained 




Table 4.37 KEGG analysis of mRNAs have significant correlation with up regulated miRNAs  
Term Fold Enrichment P-value Benjamini 
mmu04144:Endocytosis 2.86 0.001 0.12 
mmu05412:Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
3.85 0.009 0.42 
mmu05200:Pathways in cancer 2.04 0.010 0.34 
mmu04960:Aldosterone-regulated sodium reabsorption 4.91 0.018 0.42 
mmu00600:Sphingolipid metabolism 4.91 0.018 0.42 
mmu04666:Fc gamma R-mediated phagocytosis 2.95 0.030 0.52 
mmu04510:Focal adhesion 2.08 0.048 0.63 
mmu04142:Lysosome 2.43 0.07 0.69 
mmu04810:Regulation of actin cytoskeleton 1.90 0.08 0.70 
mmu00071:Fatty acid metabolism 3.67 0.09 0.73 
 
Table 4.37. KEGG pathway found by DAVID online software in Neural Tube data. We analyzed intersection 
gene list of predicted target gene list and mRNAs with significant correlation by DAVID. The intersection 
list contained 456 genes.  
 
Then, we produced the similar process of KEGG pathway analysis on GO analysis. FDR adjusted p-values 
from these pathways are given in Table 4.38. For comparison purposes, the results from DAVID analysis of 
the GO database with default parameters based on all 5,154 putative targets, the 530 intersection of these 
targets with the 3,037 DE down regulated genes and the 456 intersection of putative target genes and those 




Table 4.38. GO pathway analysis by Multiple canonical vectors and Self-contained test 
GO GO Term Statistic P-Value 
Adjust P-
value 
GO:0000086 G2/M transition of mitotic cell cycle 0.52 p< 0.001 p< 0.001 
GO:0000122 
negative regulation of transcription from RNA 
polymerase II promoter 1.74 
p< 0.001 p< 0.001 
GO:0000165 MAPK cascade 0.82 p< 0.001 p< 0.001 
GO:0000187 activation of MAPK activity 0.394 p< 0.001 p< 0.001 
GO:0000266 mitochondrial fission 0.363 p< 0.001 p< 0.001 
GO:0000904 cell morphogenesis involved in differentiation 1.417 p< 0.001 p< 0.001 
GO:0001501 skeletal system development 0.432 p< 0.001 p< 0.001 
GO:0001503 ossification 1.125 p< 0.001 p< 0.001 
GO:0001525 angiogenesis 0.873 p< 0.001 p< 0.001 
GO:0001568 blood vessel development 0.986 p< 0.001 p< 0.001 
GO:0001569 patterning of blood vessels 0.467 p< 0.001 p< 0.001 
GO:0001570 vasculogenesis 2.483 p< 0.001 p< 0.001 
GO:0001649 osteoblast differentiation 1.626 p< 0.001 p< 0.001 
GO:0001656 metanephros development 0.452 p< 0.001 p< 0.001 
GO:0001657 ureteric bud development 1.815 p< 0.001 p< 0.001 
GO:0001658 branching involved in ureteric bud morphogenesis 1.928 p< 0.001 p< 0.001 
GO:0001666 response to hypoxia 2.633 p< 0.001 p< 0.001 
GO:0001701 in utero embryonic development 1.708 p< 0.001 p< 0.001 
GO:0001708 cell fate specification 0.728 p< 0.001 p< 0.001 
GO:0001709 cell fate determination 0.931 p< 0.001 p< 0.001 
 
Table 4.38. GO pathway found by SCCA and GSEA method in Neural Tube data. We list first 20 pathways 




Table 4.39. GO analysis of predicted targets mRNAs of up regulated miRNAs 
GO Term Fold Enrichment P-Value Benjamini 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 
2.17 p<0.001 p<0.001 
GO:0045449~regulation of transcription 1.53 p<0.001 p<0.001 
GO:0051252~regulation of RNA metabolic process 1.60 p<0.001 p<0.001 
GO:0006355~regulation of transcription, DNA-dependent 1.59 p<0.001 p<0.001 
GO:0030528~transcription regulator activity 1.64 p<0.001 p<0.001 
GO:0010604~positive regulation of macromolecule 
metabolic process 
1.87 p<0.001 p<0.001 
GO:0045944~positive regulation of transcription from RNA 
polymerase II promoter 
2.20 p<0.001 p<0.001 
GO:0016568~chromatin modification 2.54 p<0.001 p<0.001 
GO:0006350~transcription 1.46 p<0.001 p<0.001 
GO:0045893~positive regulation of transcription, DNA-
dependent 
2.08 p<0.001 p<0.001 
GO:0051254~positive regulation of RNA metabolic process 2.07 p<0.001 p<0.001 
GO:0045941~positive regulation of transcription 1.99 p<0.001 p<0.001 
GO:0010628~positive regulation of gene expression 1.97 p<0.001 p<0.001 
GO:0000267~cell fraction 1.88 p<0.001 p<0.001 
GO:0009792~embryonic development ending in birth or 
egg hatching 
2.04 p<0.001 p<0.001 
GO:0048514~blood vessel morphogenesis 2.62 p<0.001 p<0.001 
GO:0045935~positive regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process 
1.91 p<0.001 p<0.001 
GO:0043009~chordate embryonic development 2.02 p<0.001 p<0.001 
GO:0003677~DNA binding 1.42 p<0.001 p<0.001 
GO:0046872~metal ion binding 1.25 p<0.001 p<0.001 
 
Table 4.39. GO pathway found by DAVID online software in Neural Tube data. We analyzed predicted 
target gene list of 52 up regulated miRNAs by DAVID. The putative target list contained 5,154 genes. We 




Table. 4.40. GO analysis of mRNAs from intersection of different data base of up regulated miRNAs 
Term 
Fold 
Enrichment P-value Benjamini 
GO:0003700~transcription factor activity 2.69 p<0.001 p<0.001 
GO:0009792~embryonic development ending in birth or egg 
hatching 
3.22 p<0.001 p<0.001 
GO:0030528~transcription regulator activity 2.10 p<0.001 p<0.001 
GO:0043565~sequence-specific DNA binding 2.80 p<0.001 p<0.001 
GO:0043009~chordate embryonic development 3.04 p<0.001 p<0.001 
GO:0007389~pattern specification process 3.57 p<0.001 p<0.001 
GO:0007507~heart development 3.96 p<0.001 p<0.001 
GO:0001944~vasculature development 3.71 0.001 p<0.001 
GO:0035239~tube morphogenesis 4.39 0.001 p<0.001 
GO:0003677~DNA binding 1.75 0.001 p<0.001 
GO:0001568~blood vessel development 3.62 0.001 p<0.001 
GO:0048729~tissue morphogenesis 3.52 0.002 0.002 
GO:0045893~positive regulation of transcription, DNA-
dependent 
2.76 0.003 0.002 
GO:0035295~tube development 3.34 0.003 0.001 
GO:0051254~positive regulation of RNA metabolic process 2.74 0.003 0.001 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 
2.36 0.004 0.001 
GO:0045944~positive regulation of transcription from RNA 
polymerase II promoter 
2.83 0.004 0.003 
GO:0045941~positive regulation of transcription 2.51 0.005 0.003 
GO:0048568~embryonic organ development 3.30 0.005 0.004 
GO:0048705~skeletal system morphogenesis 4.41 0.008 0.004 
 
Table 4.40. GO pathway found by DAVID online software in Neural Tube data. We analyzed intersection 
gene list of predicted target gene list and down-regulated mRNAs by DAVID. The intersection list contained 




Table. 4.41. GO analysis of mRNAs have significant correlation with up regulated miRNAs  
Term Fold Enrichment P-value Benjamini 
GO:0010033~response to organic substance 2.80 p<0.001 p<0.001 
GO:0043566~structure-specific DNA binding 2.16 p<0.001 p<0.001 
GO:0005829~cytosol 3.20 p<0.001 p<0.001 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 
2.73 p<0.001 p<0.001 
GO:0003690~double-stranded DNA binding 3.03 p<0.001 p<0.001 
GO:0051173~positive regulation of nitrogen compound 
metabolic process 
1.80 p<0.001 p<0.001 
GO:0045944~positive regulation of transcription from RNA 
polymerase II promoter 
3.44 p<0.001 0.001 
GO:0042493~response to drug 3.81 p<0.001 0.001 
GO:0031328~positive regulation of cellular biosynthetic 
process 
3.57 p<0.001 0.001 
GO:0009891~positive regulation of biosynthetic process 4.22 p<0.001 0.001 
GO:0042802~identical protein binding 3.48 p<0.001 0.001 
GO:0045893~positive regulation of transcription, DNA-
dependent 
3.39 p<0.001 0.003 
GO:0051254~positive regulation of RNA metabolic process 3.22 p<0.001 0.003 
GO:0010604~positive regulation of macromolecule 
metabolic process 
2.65 p<0.001 0.003 
GO:0010557~positive regulation of macromolecule 
biosynthetic process 
2.63 p<0.001 0.003 
GO:0045935~positive regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process 
2.27 p<0.001 0.003 
GO:0048732~gland development 4.86 p<0.001 0.010 
GO:0045941~positive regulation of transcription 2.73 p<0.001 0.005 
GO:0016564~transcription repressor activity 1.63 p<0.001 0.005 
GO:0010628~positive regulation of gene expression 4.25 p<0.001 0.006 
 
Table 4.41. GO pathway found by DAVID online software in Neural Tube data. We analyzed intersection 
gene list of predicted target gene list and mRNAs with significant correlation by DAVID. The intersection 




The second part was the results of 131 down regulated miRNAs, the process of analyzing was similar to the 
analysis of the 52 up regulated miRNAs. First, we determined three lists of target mRNAs which we would 
use in the later analysis with DAVID. The first list contained 8,804 genes, the second list consisted of 671 
genes and there were 1,114 genes in the third list. 
After getting the three lists, we used the SCCA method based on the expression data from the 131 down-
regulated miRNAs on GD 9.5 relative to GD 8.5and all the 10,336 filtered mRNA expression data from the 
mouse4302 chip. After normalizing each of the matrices so that expression measurements for each miRNA / 
mRNA had mean zero and standard deviation one, the miRNA data was multiplied by -1. The CCA.permute 
function in package PMA (Witten, et al., 2009) was used to determine optimal penalty parameters for SCCA 
with a single set of canonical variables.  In the result, there were 5,479 non-zero elements in the 𝒖 vector, 
which meant that 5,479 mRNAs were selected by the SCCA function. And there were 43 non-zero elements 
in 𝒗 vector, which indicated 43 miRNAs were selected. 
The next step was KEGG pathway analysis with the SCCA GSEA method. We first used the 
GeneSetCollection function within the Bioconductor package GSEABase to construct a collection of gene 
sets of pathways from the KEGG database. There were 224 pathways collected from KEGG. FDR adjusted 
p-values from these pathways are given in Table 4.42. For comparison purposes, the results from DAVID 
analysis of the KEGG database with default parameters based on all 8,804 putative targets, the 671 
intersection of these targets with the 2,838 DE up-regulated genes and the intersection of putative target genes 
and 1,114 genes with significant negative pair-wise correlation with the differentially expressed miRNAs are 




Table 4.42. KEGG pathway analysis by Multiple canonical vectors and Self-contained test 
Pathway Statistic P-value Adj.P-value 
Fatty acid elongation in mitochondria 3.527 p< 0.001 p< 0.001 
Steroid biosynthesis 1.627 p< 0.001 p< 0.001 
Pyrimidine metabolism 3.092 p< 0.001 p< 0.001 
One carbon pool by folate 4.865 p< 0.001 p< 0.001 
DNA replication 3.348 p< 0.001 p< 0.001 
Nucleotide excision repair 1.509 p< 0.001 p< 0.001 
Mismatch repair 2.181 p< 0.001 p< 0.001 
Parkinson's disease 3.070 p< 0.001 p< 0.001 
Oxidative phosphorylation 2.096 0.003 0.065 
Protein export 2.222 0.003 0.065 
Aminoacyl-tRNA biosynthesis 1.330 0.005 0.091 
Ribosome biogenesis in eukaryotes 2.825 0.005 0.091 
Ribosome 2.310 0.010 0.168 
RNA polymerase 1.042 0.014 0.218 
Selenocompound metabolism 0.867 0.030 0.436 
Huntington's disease 1.104 0.033 0.436 
Terpenoid backbone biosynthesis 1.175 0.035 0.436 
Valine, leucine and isoleucine degradation 1.131 0.036 0.436 
RNA transport 2.386 0.039 0.447 
 
Table 4.42. KEGG pathway found by SCCA and GSEA method in Neural Tube data. We list first 20 KEGG 




Table 4.43 KEGG Pathway analysis of preticted targets of down regulated miRNAs 
Pathway Fold Enrichment P-value Benjamini 
mmu04360:Axon guidance 3.00 p< 0.001 p< 0.001 
mmu05200:Pathways in cancer 2.15 p< 0.001 p< 0.001 
mmu04510:Focal adhesion 2.47 p< 0.001 p< 0.001 
mmu04310:Wnt signaling pathway 2.48 p< 0.001 p< 0.001 
mmu04810:Regulation of actin cytoskeleton 2.18 p< 0.001 p< 0.001 
mmu04010:MAPK signaling pathway 2.02 p< 0.001 p< 0.001 
mmu05210:Colorectal cancer 2.84 p< 0.001 p< 0.001 
mmu05211:Renal cell carcinoma 2.84 p< 0.001 p< 0.001 
mmu04722:Neurotrophin signaling pathway 2.19 p< 0.001 p< 0.001 
mmu04520:Adherens junction 2.62 p< 0.001 p< 0.001 
mmu04350:TGF-beta signaling pathway 2.48 p< 0.001 p< 0.001 
mmu05218:Melanoma 2.64 p< 0.001 p< 0.001 
mmu05220:Chronic myeloid leukemia 2.54 p< 0.001 p< 0.001 
mmu04530:Tight junction 2.11 p< 0.001 p< 0.001 
mmu04012:ErbB signaling pathway 2.42 p< 0.001 p< 0.001 
mmu05221:Acute myeloid leukemia 2.79 p< 0.001 p< 0.001 
mmu04144:Endocytosis 1.86 p< 0.001 p< 0.001 
mmu04910:Insulin signaling pathway 2.06 p< 0.001 p< 0.001 
P00034:Integrin signalling pathway 1.60 p< 0.001 p< 0.001 
mmu04666:Fc gamma R-mediated phagocytosis 2.26 p< 0.001 p< 0.001 
 
 
Table 4.43. KEGG pathway found by DAVID online software in Neural Tube data. We analyzed predicted 
target gene list of 131 down regulated miRNAs by DAVID. The putative target list contained 8,804 genes. 




Table. 4.44. KEGG Pathway analysis of mRNAs from intersection of different data base of down 
regulated miRNAs 
Pathway Fold Enrichment P-value Benjamini 
mmu04360:Axon guidance 4.76 p< 0.001 p< 0.001 
mmu04310:Wnt signaling pathway 3.66 p< 0.001 p< 0.001 
mmu04510:Focal adhesion 3.15 p< 0.001 p< 0.001 
mmu05200:Pathways in cancer 2.41 p< 0.001 p< 0.001 
mmu05210:Colorectal cancer 4.23 p< 0.001 p< 0.001 
mmu04010:MAPK signaling pathway 2.55 p< 0.001 p< 0.001 
mmu04666:Fc gamma R-mediated phagocytosis 3.71 p< 0.001 p< 0.001 
mmu04330:Notch signaling pathway 5.19 p< 0.001 p< 0.001 
mmu05220:Chronic myeloid leukemia 4.10 p< 0.001 p< 0.001 
mmu05214:Glioma 4.46 p< 0.001 p< 0.001 
mmu05221:Acute myeloid leukemia 4.56 p< 0.001 p< 0.001 
mmu05213:Endometrial cancer 4.49 p< 0.001 p< 0.001 
mmu05223:Non-small cell lung cancer 4.33 p< 0.001 p< 0.001 
mmu04664:Fc epsilon RI signaling pathway 3.48 p< 0.001 p< 0.001 
mmu04912:GnRH signaling pathway 3.21 p< 0.001 p< 0.001 
mmu04914:Progesterone-mediated oocyte maturation 3.36 p< 0.001 p< 0.001 
mmu04810:Regulation of actin cytoskeleton 2.27 p< 0.001 p< 0.001 
mmu05212:Pancreatic cancer 3.61 p< 0.001 p< 0.001 
mmu04660:T cell receptor signaling pathway 2.86 p< 0.001 p< 0.001 
mmu05215:Prostate cancer 3.17 p< 0.001 p< 0.001 
 
Table 4.44. KEGG pathway found by DAVID online software in Neural Tube data. We analyzed intersection 
gene list of predicted target gene list and down-regulated mRNAs of 131 down regulated miRNAs by DAVID. 




Table. 4.45. KEGG analysis of mRNAs have significant correlation with down regulated miRNAs  
Pathway Fold Enrichment P-Value Benjamini 
mmu04360:Axon guidance 4.62 p< 0.001 p< 0.001 
mmu04310:Wnt signaling pathway 3.76 p< 0.001 p< 0.001 
mmu04010:MAPK signaling pathway 2.79 p< 0.001 p< 0.001 
mmu04510:Focal adhesion 3.06 p< 0.001 p< 0.001 
mmu05210:Colorectal cancer 4.17 p< 0.001 p< 0.001 
mmu05200:Pathways in cancer 2.36 p< 0.001 p< 0.001 
2.7.11.1 2.35 p< 0.001 0.005 
mmu04810:Regulation of actin cytoskeleton 2.48 p< 0.001 0.001 
mmu04666:Fc gamma R-mediated phagocytosis 3.43 p< 0.001 0.001 
mmu05214:Glioma 4.20 p< 0.001 0.001 
mmu05220:Chronic myeloid leukemia 3.83 p< 0.001 0.001 
P00057:Wnt signaling pathway 1.76 p< 0.001 0.016 
mmu04660:T cell receptor signaling pathway 3.04 p< 0.001 0.002 
mmu04330:Notch signaling pathway 4.48 p< 0.001 0.003 
mmu04910:Insulin signaling pathway 2.76 p< 0.001 0.004 
mmu05213:Endometrial cancer 4.31 p< 0.001 0.004 
mmu04012:ErbB signaling pathway 3.35 p< 0.001 0.004 
mmu05223:Non-small cell lung cancer 4.15 p< 0.001 0.004 
P00005:Angiogenesis 1.87 p< 0.001 0.029 
mmu05221:Acute myeloid leukemia 3.93 p< 0.001 0.006 
 
Table 4.45. KEGG pathway found by DAVID online software in Neural Tube data. We analyzed intersection 
gene list of predicted target gene list and mRNAs with significant correlation by DAVID. The intersection 




Then, we produced a similar analysis on based on the GO database. FDR adjusted p-values from these terms 
for the SCCA-GSEA method are given in Table 4.46. For comparison purposes, the results from DAVID 
analysis of the GO database with default parameters based on all 8,804 putative targets, the 671 intersection 
of these targets with the 2,838 DE up-regulated genes and the 1,114 intersection of putative target genes and 




Table 4.46. GO pathway analysis by Multiple canonical vectors and Self-contained test 
GO ID GO Term Statistic P-Value 
Adjust P-
value 
GO:0000028 ribosomal small subunit assembly 0.438 p< 0.001 p< 0.001 
GO:0000038 very long-chain fatty acid metabolic process 2.59 p< 0.001 p< 0.001 
GO:0000056 ribosomal small subunit export from nucleus 1.324 p< 0.001 p< 0.001 
GO:0000076 DNA replication checkpoint 0.482 p< 0.001 p< 0.001 




p< 0.001 p< 0.001 
GO:0000778 condensed nuclear chromosome kinetochore 0.432 p< 0.001 p< 0.001 
GO:0000785 chromatin 2.181 p< 0.001 p< 0.001 
GO:0000801 central element 3.039 p< 0.001 p< 0.001 
GO:0001940 male pronucleu 4.261 p< 0.001 p< 0.001 
GO:0003406 retinal pigment epithelium development 0.602 p< 0.001 p< 0.001 
GO:0003723 RNA binding 3.199 p< 0.001 p< 0.001 
GO:0003729 mRNA binding 2.598 p< 0.001 p< 0.001 
GO:0003735 structural constituent of ribosome 3.731 p< 0.001 p< 0.001 
GO:0003777 microtubule motor activity 4.139 p< 0.001 p< 0.001 
GO:0003796 lysozyme activity 1.708 p< 0.001 p< 0.001 
GO:0003857 3-hydroxyacyl-CoA dehydrogenase activity 2.991 p< 0.001 p< 0.001 
GO:0004111 creatine kinase activity 2.848 p< 0.001 p< 0.001 
GO:0004322 ferroxidase activity 2.041 p< 0.001 p< 0.001 
GO:0004402 histone acetyltransferase activity 2.504 p< 0.001 p< 0.001 
 
Table 4.46. GO pathway found by SCCA and GSEA method in Neural Tube data. We list first 20 GO 




Table. 4.47. GO analysis of preticted targets mRNAs of down regulated miRNAs 
Term Fold Enrichment P-value Benjamini 
GO:0045449~regulation of transcription 1.53 p< 0.001 p< 0.001 
GO:0003677~DNA binding 1.56 p< 0.001 p< 0.001 
GO:0006350~transcription 1.56 p< 0.001 p< 0.001 
GO:0030528~transcription regulator activity 1.71 p< 0.001 p< 0.001 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 
2.01 
p< 0.001 p< 0.001 
GO:0045941~positive regulation of transcription 2.00 p< 0.001 p< 0.001 
GO:0045935~positive regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process 
1.95 
p< 0.001 p< 0.001 
GO:0010628~positive regulation of gene expression 1.97 p< 0.001 p< 0.001 
GO:0045893~positive regulation of transcription, DNA-
dependent 
2.06 
p< 0.001 p< 0.001 
GO:0051254~positive regulation of RNA metabolic process 2.04 p< 0.001 p< 0.001 
GO:0003700~transcription factor activity 1.72 p< 0.001 p< 0.001 
GO:0051173~positive regulation of nitrogen compound 
metabolic process 
1.90 
p< 0.001 p< 0.001 
GO:0010604~positive regulation of macromolecule 
metabolic process 
1.81 
p< 0.001 p< 0.001 
GO:0043009~chordate embryonic development 2.01 p< 0.001 p< 0.001 
GO:0009792~embryonic development ending in birth or 
egg hatching 
2.00 
p< 0.001 p< 0.001 
GO:0010557~positive regulation of macromolecule 
biosynthetic process 
1.88 
p< 0.001 p< 0.001 
GO:0045944~positive regulation of transcription from RNA 
polymerase II promoter 
2.10 
p< 0.001 p< 0.001 
GO:0031328~positive regulation of cellular biosynthetic 
process 
1.84 
p< 0.001 p< 0.001 
GO:0009891~positive regulation of biosynthetic process 1.84 p< 0.001 p< 0.001 
GO:0051252~regulation of RNA metabolic process 1.44 p< 0.001 p< 0.001 
 
Table 4.47. GO pathway found by DAVID online software in Neural Tube data. We analyzed predicted 
target gene list of 131 down regulated miRNAs by DAVID. The putative target list contained 8,804 genes. 




Table. 4.48. GO analysis of mRNAs from intersection of different data base of down regulated 
miRNAs 
GO Term Fold Enrichment P-value Benjamini 
GO:0045449~regulation of transcription 1.81 p< 0.001 p< 0.001 
GO:0003677~DNA binding 1.88 p< 0.001 p< 0.001 
GO:0006350~transcription 1.81 p< 0.001 p< 0.001 
GO:0030528~transcription regulator activity 2.01 p< 0.001 p< 0.001 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 
2.33 p< 0.001 p< 0.001 
GO:0016568~chromatin modification 3.35 p< 0.001 p< 0.001 
GO:0030182~neuron differentiation 2.68 p< 0.001 p< 0.001 
GO:0010629~negative regulation of gene expression 2.61 p< 0.001 p< 0.001 
GO:0005856~cytoskeleton 1.92 p< 0.001 p< 0.001 
GO:0010558~negative regulation of macromolecule 
biosynthetic process 
2.56 p< 0.001 p< 0.001 
GO:0032990~cell part morphogenesis 3.33 p< 0.001 p< 0.001 
GO:0016481~negative regulation of transcription 2.65 p< 0.001 p< 0.001 
GO:0044451~nucleoplasm part 2.46 p< 0.001 p< 0.001 
GO:0048667~cell morphogenesis involved in neuron 
differentiation 
3.53 p< 0.001 p< 0.001 
GO:0031327~negative regulation of cellular biosynthetic 
process 
2.49 p< 0.001 p< 0.001 
GO:0005654~nucleoplasm 2.31 p< 0.001 p< 0.001 
GO:0009890~negative regulation of biosynthetic process 2.47 p< 0.001 p< 0.001 
GO:0007409~axonogenesis 3.68 p< 0.001 p< 0.001 
GO:0048812~neuron projection morphogenesis 3.53 p< 0.001 p< 0.001 
GO:0051252~regulation of RNA metabolic process 1.68 p< 0.001 p< 0.001 
 
Table 4.48. GO pathway found by DAVID online software in Neural Tube data. We analyzed intersection 
gene list of predicted target gene list and down-regulated mRNAs of 131 down regulated miRNAs by DAVID. 




Table. 4.49. GO analysis of mRNAs have significant correlation with down regulated miRNAs  
Term Fold Enrichment P-value Benjamini 
GO:0045449~regulation of transcription 1.76 p< 0.001 p< 0.001 
GO:0003677~DNA binding 1.83 p< 0.001 p< 0.001 
GO:0030528~transcription regulator activity 2.00 p< 0.001 p< 0.001 
GO:0006350~transcription 1.77 p< 0.001 p< 0.001 
GO:0030182~neuron differentiation 2.71 p< 0.001 p< 0.001 
GO:0044451~nucleoplasm part 2.51 p< 0.001 p< 0.001 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 
2.25 p< 0.001 p< 0.001 
GO:0005654~nucleoplasm 2.33 p< 0.001 p< 0.001 
GO:0032990~cell part morphogenesis 3.22 p< 0.001 p< 0.001 
GO:0048667~cell morphogenesis involved in neuron 
differentiation 
3.44 p< 0.001 p< 0.001 
GO:0007409~axonogenesis 3.61 p< 0.001 p< 0.001 
GO:0016568~chromatin modification 3.06 p< 0.001 p< 0.001 
GO:0048812~neuron projection morphogenesis 3.45 p< 0.001 p< 0.001 
GO:0010629~negative regulation of gene expression 2.45 p< 0.001 p< 0.001 
GO:0031981~nuclear lumen 1.97 p< 0.001 p< 0.001 
GO:0048858~cell projection morphogenesis 3.19 p< 0.001 p< 0.001 
GO:0048666~neuron development 2.73 p< 0.001 p< 0.001 
GO:0031175~neuron projection development 3.05 p< 0.001 p< 0.001 
GO:0051252~regulation of RNA metabolic process 1.63 p< 0.001 p< 0.001 
GO:0010558~negative regulation of macromolecule 
biosynthetic process 
2.36 p< 0.001 p< 0.001 
 
Table 4.49. GO pathway found by DAVID online software in Neural Tube data. We analyzed intersection 
gene list of predicted target gene list and mRNAs with significant correlation by DAVID. The intersection 




CHAPTER V  
METHOD OF INTEGRATED ANALYSIS OF MRNA AND METHYLATION 
5.1. Application of sparse mCCA to Murine Palate Methylome data 
In our previous chapters, we showed that sparse CCA can perform an integrative analysis on two data sets 
with the same number of samples but different variables. But now, we need to analyze more than two data 
sets. (Gifi, 1990) introduced a number of methods that generalized CCA to more than two data sets, and 
Witten and Tibshirani (Witten and Tibshirani, 2009) extended their sparse CCA approach to sparse multiple 
CCA (mCCA).  Here, we briefly review their methodology with the context of applying it to our genomewide 
methylation data. In our application we use methylated DNA probes from 21 chromosomes collected from 
the murine embryonic palate during gestational days (GDs) 12 to 14 (three arrays per GD) (Seelan, et al., 
2013). We have M = 21 data sets 𝑿𝟏, 𝑿𝟐 … 𝑿𝟐𝟎, , and there are 𝒑𝒎 variables (here, probes in methylated 
regions) and 𝑛 samples for data set 𝑿𝒎 where m= 1,2…21, n= 9 in our research. We normalized each variable 
in the data sets to have mean 0 and standard deviation 1. Then, the criterion of multiple CCA for obtaining 
weight vectors 𝒘𝟏, 𝒘𝟐 … 𝒘𝟐𝟎 is to maximize  
∑ 𝒘𝒊
𝑻𝑿𝒊
𝑻𝑿𝒋𝒊<𝒋 𝒘𝒋 subject to 𝒘𝒎
𝑻 𝑿𝒎
𝑻 𝑿𝒎𝒘𝒎 = 1, ∀𝑚,  where 𝑤𝑚 ∈ ℝ
𝑝𝑚 . 
As can be seen, when M = 2 multiple CCA reduces to traditional CCA. Following this logical spirit, Witten 
and Tibshirani (2009) extended the criterion for SCCA with two data sets to sparse multiple CCA. Again, we 
suppose the samples within each data set are independent so that 𝑿𝒎
𝑻 𝑿𝒎 = 𝑰 for any m. Then the criterion 
for sparse mCCA is: 𝑚𝑎𝑥𝑖𝑚𝑖𝑧𝑒 𝒘𝟏,𝒘𝟐…𝒘𝑴 ∑ 𝒘𝒊
𝑻𝑿𝒊
𝑻𝑿𝒋𝒊<𝒋 𝒘𝒋 subject to ‖𝒘𝒊‖
2 ≤ 1, 𝑃𝑖(𝒘𝒊) ≤ 𝑐𝑖 , ∀𝑖 , 
where 𝑃𝑖  is a lasso or fused lasso penalty. When 𝑐𝑖is set appropriately, the canonical vector 𝒘𝒊 which related 




The algorithm of Witten and Tibshirani (2009) for calculating the canonical weight vectors of the sparse 
mCCA is:1. Set initial value for each.𝒘𝒊 ∈ ℝ
𝑝𝑚2. For every data set, we repeat iteration until the canonical 
vector 𝒘𝒊converges:  
𝒘𝒊 ← 𝑎𝑟𝑔𝑚𝑎𝑥𝒘𝒊𝒘𝒊
𝑻𝑿𝒊
𝑻(∑ 𝑿𝒋𝒋≠𝒊 𝒘𝒋) subject to ‖𝒘𝒊‖
2 ≤ 1, 𝑃𝑖(𝒘𝒊) ≤ 𝑐𝑖 For the example of L1 penalty of 𝑃𝑖  
the update of 𝒘𝒊 follows the form as: 
𝒘𝒊 ←
𝑆(𝑿𝒊
𝑻(∑ 𝑿𝒋𝒋≠𝒊 𝒘𝒋), Δ𝑖)
‖𝑆(𝑿𝒊
𝑻(∑ 𝑿𝒋𝒋≠𝒊 𝒘𝒋), 𝛥𝑖)‖2
 
When ‖𝒘𝒊‖1 = 𝑐𝑖 we choose Δ𝑖 > 0, in addition`Δ𝑖 = 0 when ‖𝒘𝒊‖1 < 𝑐𝑖. 
Witten and Tibshirani (2009) used the sparse mCCA approach to investigate genome wide correlation in 
copy number patterns. In our research, we posed a similar question concerning whether the methylated probes 
on separate chromosomes have similar changes in pattern.  Hence, we apply sparse mCCA on data sets 𝑋𝑖 
where 𝑖 = 1,2 … 21, each contains methylated probes on chromosome i. Because the methylated probes are 
ordered along the chromosome, a fused lasso penalty is used on all data sets. 
 
5.2. Integrated analysis of methylated regions of interest (MRIs) measurements and mRNA expression 
using SCCA 
In this part we first identify the DE mRNAs (up and down-regulated between GD 12 and 14) which have 
maximum negative correlation with MRIs. We determine the correlation between MRIs and mRNAs by the 
SCCA method which we described in the previous section. The procedure is similar to the integrated analysis 
of miRNA and mRNA expression using SCCA. Suppose there are two types of data sets 𝑿𝒊𝟏 and 𝑿𝒊2 with 
the same number of observations n, where 𝑖 = 1,2 … , 21 (the total number of chromosomes). In our 
application, the first type of data matrix 𝑿𝒊𝟏has dimension 𝑛 × 𝑝𝑖1 (𝑝𝑖1 variables with n observations, where 
𝑖 = 1,2 … 21) indicates DE mRNAs in each chromosome.  The second type of data matrix 𝑿𝒊𝟐 has dimension 
𝑛 × 𝑝𝑖2 (𝑝𝑖2 variables with n observations, where 𝑖 = 1,2 … 21) represents MRIs in each chromosome. For 
any pair of these two data sets under same chromosome, we first identify DE genes (up and down-regulated 
between GD 12 and 14) and MRIs. Second, for each chromosome the entire set of DE gene expression 
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measurements and the entire set of MRIs will be analyzed using SCCA to determine how the global changes 
in methylation patterns along the chromosome impact gene expression patterns on the chromosome.  Since 
methylation measurements are ordered along the chromosome, we should follow (Witten and Tibshirani, 
2009) and use the lasso penalty (Tibshirani, 1996) on the matrix of mRNA expression measurements and the 
fused lasso penalty (Tibshirani, et al., 2005) on the matrix of methylation measurements. However, for GSEA 
we need to create the gene set scores from the weight vectors obtained from SCCA and hence we need the 
weight vectors to be positive. Since the SCCA software requires using the same penalty for each data set to 
obtain positive weight vectors, we also use the lasso penalty on the MRIs matrix. After the SCCA process, 
we again create a GSEA statistic on the basis of the SCCA analysis, similar in spirit to the statistic for 
integrating miRNA and mRNA expression data.   
Since we apply integrated analysis of MRIs and mRNA on separate chromosomes, we create GSEA statistics 
for each chromosome. After the SCCA procedure, we obtain the weight vectors 𝒖𝒊 and 𝒗𝒊 on chromosome i, 
where i= 1, 2…21, 𝒖𝒊 is the weight vector of mRNA expression matrix of chromosome i with dimensional 
1 × 𝑝𝑖1and 𝒗𝒊 is the weight vector of MRI probe intensity matrix of chromosome i with dimensional 1 × 𝑝𝑖2.  
The test statistic is constructed from two parts. The first part consists of the normalized 𝒖𝒊 vector 𝒖𝒊norm, such 
that the mean of 𝒖𝒊norm is zero and the variance is one. This component simply indicates the genes that are 
represented in the weight vector 𝒖𝒊 . The second part consists of the averaged MRI probe scores which 
correlate with specific genes selected by SCCA. This component incorporates the weights associated with 
MRI probe scores into the per-gene scores. We first map the MRI probes to the nearest gene. Second, we 
calculated the averaged score of MRI probes for each gene and called the new vector 𝒗𝒊
∗with dimension 1 ×
𝑝𝑖1; same with 𝒖𝒊 The 𝒗𝒊
∗ scores are also normalized to have mean zero and standard deviation one (𝒗𝒊norm
∗ ). 
Lastly, we set the final statistic associated with each gene by summing the normalized 𝒖𝒊 and 𝒗𝒊
∗ scores and 
then dividing by √2, which is denoted as 𝒁𝒊 =
1
√2
(𝒖𝒊 norm + 𝒗𝒊norm
∗ ).  
Then, we calculate an aggregate gene enrichment score for each pre-determined gene set. Suppose there are 
K pre-determined gene sets with 𝑛1, 𝑛2, … , 𝑛𝐾 genes in each set.  In our terminology, the vector 𝒁𝑖𝑗consists 
of the components of 𝒁𝒊  corresponding to the genes in gene set 𝑗 . Then, the GSEA statistic 
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𝑔𝑠1(𝒁𝑖1),  𝑔𝑠2(𝒁𝑖2), … , 𝑔𝑠𝐾(𝒁𝑖𝐾) for each gene set is calculated by the sum of the per gene statistic included 
in each gene set then divided by the square root of the number of genes in each gene set:  







where 𝑘 = 1,2, … , 𝐾 and 𝒁𝑖𝑘 = (𝑧𝑖1,  𝑧𝑖2, … ,  𝑧𝑖𝑛𝑘) are the gene statistics for gene set 𝑔𝑠𝑘. 
Finally, we calculate the permutation p-value of the GSEA statistic for each gene set using competitive test. 
We first resample the per-gene statistics 𝒁𝒊  = (𝑧𝑖1,  𝑧𝑖2, … ,  𝑧𝑖𝑝1) without replacement to obtain permuted 
statistics 𝒁𝒊




















, … , 𝑧𝑖𝑛𝑘
𝑝
) are the permuted gene statistics for each gene set 𝑔𝑠𝑘. The permutation p-value 𝑝perm,𝑘 for 
each gene-set 𝑘 is then calculated as the proportion of the permuted GSEA statistics that are larger than the 
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REAL DATA ANALYSIS OF MURINE PALATAL METHYLOME DATA 
The original methylation data set obtained from the developing secondary palate of mouse embryos was 
collected using NimbleGen 2.1M mouse promoter arrays (Seelan, et al., 2013). Data were analyzed using the 
Bioconductor package Ringo(Toedling, et al., 2007). It contained three arrays per each gestational day (GD), 
GD 12, 13, and 14. The total number of samples in the original methylation data was 9 and the number of 
probes was 2,064,266. The mRNA data was collected in prior studies using Affymetrix GENECHIP analysis 
software and the annotation of the data was mgu74av2. The number of samples in the mRNA data was 9 
(three per GD) and the number of genes was 21,706. Since the gene expression data was collected in prior 
studies and the samples were different for the methylation data, we averaged the data by GD when we did 
integrated gene expression and methylation data analysis. 
In the analysis, we first filtered the data set. For the original methylation data, there were 2,064,266 probes 
and 9 samples. We kept the 70,072 methylation probes which were in methylated regions (Seelan et al, 2013) 
and averaged the data by GD day. In the mRNA expression data, we used the function nsFilter within R 
package genefilter to filter the mRNA data by removing duplicate probes mapping to the same Entrez Gene 
ID (the probe with the highest variance across the samples was retained) and probes with a variance below 
the 50th percentile. After filtering 12,488 probes remained and we again averaged the data by GD day.  
Second, we used sparse multiple CCA to calculate the canonical vectors at whole methylated regions to 
identify which methylated regions are correlated with each other (to identify methylated regions which have 




Figure 6.1. Sparse mCCA treating each chromosome as a separate data set, in order to identify genomic 
regions that have correlated methylation patterns. The canonical vectors w1, …, w21 are shown. Positive values 




Third, we determined differentially expressed mRNAs between GD-14 and GD-12 arrays on chromosome 1 
using the empirical Bayes method in R package limma (Ritchie, et al., 2015) (Smyth, 2004). We identified 
42 significant mRNAs with adjusted p-values (based on the Benjamini- Hochberg correction) ≤ 0.05. Nine 
out of the 42 mRNAs had a negative log fold change and were down regulated in GD-14 compared to GD-
12, and the other 33 mRNAs had a positive log fold changes and were up regulated. 
Fourth, we used the SCCA method based on the 9 down-regulated mRNAs data and the 3,157 methylated 
probes on chromosome 1. After normalizing each of the matrices so that expression measurements for each 
mRNA / Methylation had mean zero and standard deviation one, the mRNA data was multiplied by -1. The 
CCA.permute function in package PMA (Witten, et al., 2009) was used to determine the optimal penalty 
parameters for SCCA with a single set of canonical variables. In the result, there were 9 non-zero elements 
in the 𝒖 vector, which meant that 9 mRNAs were selected by the SCCA function. And there were 210 non-
zero elements in 𝒗 vector, which indicated 210 methylated probes were selected. 
The next step was GO pathway analysis with the SCCA GSEA method. We first used the GeneSetCollection 
function within the Bioconductor package GSEABase to construct a collection of gene sets of pathways from 
the GO database. There were 380 pathways collected from GO. FDR adjusted p-values from these pathways 
are given in Table 6.1. For comparison purposes, the results from DAVID analysis of the GO database with 
default parameters based on the 80 genes which mapped to the methylated probes with positive loadings in 




Table. 6.1. GO pathway analysis 
GO ID GO Term Statistic P-Value Adj.pvalue 
GO:0016311 dephosphorylation 0.274 0.007 0.820 
GO:0031225 anchored component of membrane 0.276 0.008 0.820 
GO:0005886 plasma membrane 0.666 0.010 0.820 
GO:0030016 myofibril 0.273 0.010 0.820 
GO:0005515 protein binding 1.242 0.012 0.820 
GO:0009986 cell surface 0.351 0.021 0.820 
GO:0016020 membrane 0.940 0.029 0.820 
GO:0005622 intracellular 0.491 0.042 0.820 
GO:0004035 alkaline phosphatase activity 0.183 0.049 0.820 
GO:0016791 phosphatase activity 0.183 0.049 0.820 
 










GO:0006928~cell motion enabled homolog (Drosophila);  3.778 0.040 1.000 
 
similar to SH2/SH3 adaptor protein; 
neuron navigator 1;        
  
Fc receptor, IgE, high affinity I, gamma 
polypeptide;       
  GLI-Kruppel family member GLI2       
GO:0009084~glutamine 
family amino acid 
biosynthetic process 
predicted gene 4949, glutamate-
ammonia ligase (glutamine 
synthetase);  36.974 0.052 1.000 
 
pyrroline-5-carboxylate reductase 
family, member 2       
 LMBR1 domain containing 1;   6.460 0.076 1.000 
GO:0019842~vitamin 
binding 
solute carrier family 19 
(sodium/hydrogen exchanger), 
member 3;       
  selenocysteine lyase       
GO:0005212~structural 
constituent of eye lens 
crystallin, gamma D, crystallin, gamma 
A 24.814 0.076 0.999 
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 isoleucine-tRNA synthetase 2, 
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 60 genes from our list 
are not in the output. 
 staufen (RNA binding protein) 
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calsequestrin 1;  RIKEN cDNA 
6430706D22 gene       
 
Table 6.2. GO pathway found by DAVID software in the murine palate data. We analyzed the list of genes 
on chromosome 1 which mapped to the methylated probes with positive loadings in SCCA with DAVID. 




Then, we did a similar analysis of chromosome 1 on chromosome 2. First, we determined differentially 
expressed mRNAs between GD-14 and GD-12 arrays on chromosome 2 using the empirical Bayes method 
in R package limma (Ritchie, et al., 2015) (Smyth, 2004). We identified 42 significant mRNAs with adjusted 
p-values (based on Benjamini-Hochberg correction) ≤ 0.05. Twelve out of 40 mRNAs with negative log fold 
change were down regulated on GD-14 versus GD-12, and the other 28 mRNAs had a positive log fold 
change and were up regulated. 
Fourth, we used the SCCA method based on the 12 down-regulated mRNAs and the 3,157 methylated probes 
on chromosome 2. After normalizing each of the matrices so that expression measurements for each mRNA 
/ methylation probe had mean zero and standard deviation one, the mRNA data was multiplied by -1. The 
CCA.permute function in package PMA (Witten, et al., 2009) was used to determine optimal penalty 
parameters for SCCA with a single set of canonical variables. In the result, there were 12 non-zero elements 
in the 𝒖 vector, which meant that 12 mRNAs were selected by the SCCA function. And there were 733 non-
zero elements in 𝒗 vector, which indicated 733 methylated probes were selected. 
The next step was GO pathway analysis with the SCCA GSEA method. We first used the GeneSetCollection 
function within the Bioconductor package GSEABase to construct a collection of gene sets of pathways from 
the GO database. There were 380 pathways collected from GO. FDR adjusted p-values from these pathways 
are given in Table 6.3. For comparison purposes, the results from DAVID analysis of the GO database with 
default parameters based on 76 genes which mapped to the methylated probes with positive loadings in the 
SCCA method is given in Table 6.4.  
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Table 6.3. GO Pathway analysis  
GO ID GO Term Statistic P-Value Adj.pvalue 
GO:0009791 post-embryonic development 0.434 0 0.000 
GO:0035116 embryonic hindlimb morphogenesis 0.434 0 0.000 
GO:0042995 cell projection 0.547 0 0.000 
GO:0001894 tissue homeostasis 0.334 0.001 0.012 
GO:0001958 endochondral ossification 0.334 0.001 0.012 
GO:0003924 TPase activity 0.334 0.001 0.012 
GO:0004871 signal transducer activity 0.334 0.001 0.012 
GO:0005834 heterotrimeric G-protein complex 0.334 0.001 0.012 
GO:0006112 energy reserve metabolic process 0.334 0.001 0.012 
GO:0006306 DNA methylation 0.334 0.001 0.012 
GO:0007186 G-protein coupled receptor signaling pathway 0.334 0.001 0.012 
GO:0007189 
adenylate cyclase-activating G-protein coupled 
receptor signaling pathway 0.334 0.001 0.012 
GO:0007191 
adenylate cyclase-activating dopamine receptor 
signaling pathway 0.334 0.001 0.012 
GO:0007606 sensory perception of chemical stimulus 0.334 0.001 0.012 
GO:0019001 guanyl nucleotide binding 0.334 0.001 0.012 
GO:0030425 dendrite 0.334 0.001 0.012 
GO:0031234 
extrinsic component of cytoplasmic side of plasma 
membrane 0.334 0.001 0.012 
GO:0031683 G-protein beta/gamma-subunit complex binding 0.334 0.001 0.012 
GO:0031852 mu-type opioid receptor binding 0.334 0.001 0.012 
GO:0035255 ionotropic glutamate receptor binding 0.334 0.001 0.012 
 




Table 6.4 GO pathway analysis  
Term Fold Enrichment P-value Benjamini 
GO:0030326~embryonic limb morphogenesis 11.674 0.005 0.908 
GO:0035113~embryonic appendage morphogenesis 11.674 0.005 0.908 
GO:0035137~hindlimb morphogenesis 24.978 0.006 0.799 
GO:0035108~limb morphogenesis 9.846 0.007 0.721 
GO:0035107~appendage morphogenesis 9.846 0.007 0.721 
GO:0060173~limb development 9.515 0.008 0.651 
GO:0048736~appendage development 9.515 0.008 0.651 
GO:0008219~cell death 3.350 0.030 0.958 
GO:0016265~death 3.273 0.033 0.945 
GO:0009791~post-embryonic development 9.761 0.036 0.937 
GO:0042981~regulation of apoptosis 3.071 0.041 0.936 
GO:0043067~regulation of programmed cell death 3.033 0.043 0.923 
GO:0010941~regulation of cell death 3.017 0.044 0.905 
GO:0009886~post-embryonic morphogenesis 40.440 0.047 0.900 
 
Table 6.4. GO pathway found by DAVID software in the murine palate data. We analyzed list of genes on 
chromosome 2 which mapped back to the methylated probes with positive loadings in SCCA with DAVID. 






In this research, we developed a novel GSEA approach for integrated analysis of miRNA / mRNA expression 
data and miRNA / methylation data. Our methodology uses sparse CCA to find correlated sub-dimensions in 
the two data sets, and bases the GSEA statistic on the weight vectors from this analysis.  We tested our 
methodology using multiple real and simulated data sets and compared it with standard approaches in the 
literature based on pairwise correlation analysis or the intersection of gene lists from differentially expressed 
up and down-regulated mRNAs / miRNAs.  
In the simulation study for integrated GSEA of miRNA and mRNA expression data, the PWC method has 
larger power than SCCA when the number of targeting miRNAs is small. But the SCCA method outperforms 
the PWC approach as the number of targeting miRNAs increases. This separation is greatest when the sample 
size is small and the standard deviation is large, with the power of the methods converging to each other as 
the sample size increases. As we expected, the whole simulation results support that the power of two 
methods increase as the sample size of the simulated data and the number of correlated miRNAs and mRNAs 
increase. Inversely, the power decreases as the error rate of the simulated data increases. In general we found 
that the SCCA method had better performance (higher power) than PWC.   
In the real data analysis of miRNA / mRNA expression, the SCCA-GSEA method may give a more 
reasonable number of pathways compared to DAVID analysis (gene-set analysis) using all putative targets 
of differentially expressed (DE) miRNAs and the intersection of this list with DE mRNAs. Since the number 
of putative target genes of DE miRNAs is usually quite large (several thousands), the number of significantly 
enriched pathways based on this list is correspondingly large as well. And intersecting this list with DE 
mRNAs based on a hard p-value threshold may result in the opposite problem of too few genes inthe list. 
Hence, integrated analysis using our SCCA- GSEA approach may result in a nice compromise of obtaining 
a focused list of germane pathways and biological gene sets.
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In our research, we have introduced sparse canonical correlation analysis as a method for doing integrated 
miRNA / mRNA analysis. There are also other methods for this purpose, including MMIA(Nam, et al., 2009), 
mirAct (Liang, et al., 2011), and MAGIA (Sales, et al., 2010). A drawback of the above approaches is that 
evaluating all potential miRNA / mRNA interactions using pairwise correlations can lead to significant 
reduction in power due to the number of comparisons involved. And methods that focus on pairing 
significantly up-regulated mRNAs with down-regulated miRNA counterparts (and vice-versa) (e.g., MMIA) 
potentially lose information by using a hard threshold for determining the differentially expressed (DE) list 
of mRNAs and miRNAs. As an alternative, sparse CCA is a data reduction technique that has been effective 
in the high-throughput setting for integrating gene expression and other types of ‘omics’ data. 
There are quite a few other methods for doing integrated GSEA based on multiple data sets. Poisson et al. 
(Poisson, et al., 2011) introduce two methods of integrated GSEA using both gene expression and metabolite 
information. The first is logistic regression analysis with 2-df Wald test, a multivariate extension of the 
competitive logistic regression test. In this method, they first separately modeled genes and metabolites with 
absolute per-element t-statistic. The null hypothesis of the joint test is that both regression coefficients are 
zero. Under the null hypothesis, the test statistic follows chi-square distribution with two degrees of freedom. 
The second is sum of squared statistics with a 2-dimensional permutation test, a multivariate extension of the 
self-contained sum of squared statistics. They create observed pair and null pair enrichment test statistics for 
genes and metabolites, then calculate the Mahalanobis distance from observed and null statistic pairs to the 
centroid of the sets of null pairs. Then, they calculate the joint permutation p-value as the proportion that the 
Mahalanobis distances corresponding to observed statistics are larger than or equal to the null statistic 
Mahalanobis distance.  
One obvious issue for both methods is that they are joint assessment approaches which connect per-gene and 
per-metabolite test statistics as a single vector. In most cases, gene expression and metabolites have a 
different sample size, so two-sample t statistics are not directly comparable (due to differing degrees of 
freedom). Use of p-values solves the comparability problem, but in this case the empirical p-value will lack 
precision and lose directionality. Our method avoids this issue by creating test statistics separately from both 
data sets and mapping them to the gene level. For miRNA / mRNA integrated analysis this is done by 
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incorporating the targeting matrix of miRNAs. For mRNA / methylation analysis, we map MRIs back to 
correlated genes and use averaged values of methylation probes to obtain two lists with the same size. 
Although there are many differences between our method and that of Poisson et al., the overall procedure is 
similar. First, create per-element test statistics. Then, define gene sets and create a GSEA score. Lastly, 
calculate a permutation based p-value corresponding to each gene set.  
Jiang and Gentleman (Jiang and Gentleman, 2007) start from the original GSEA which is described in 
(Subramanian, et al., 2005) and (Tian, et al., 2005). Then, they extend the method of obtaining the test statistic 
with linear modeling and posterior probabilities. They further extend the gene set aggregation function by 
using the median and sign-test rather than the mean gene set score. In the paper, they also apply the method 
on acute lymphoblastic leukemia (ALL) data to produce an incidence matrix for showing the association 
between genes and phenotypes (pre-defined gene sets). However, they do not integrate any other kind of data 
with mRNA expression data. In our research, we create putative targeting gene matrix of miRNA, in this 
case, we generate the per-gene statistic with the information both miRNA and mRNA data sets. In their paper 
they create gene statistic with three method, two-sample t-statistic, linear modeling and posterior probability 
as gene statistic. All of these methods depend on hard threshold, but our SCCA method using a soft-threshold 
to detecting the weight vectors for both data sets. In the Jiang’s paper, they create gene set statistics by three 
different summaries of the evidence for each gene set, mean, median and sign-test. Following, they produce 
a competitive permutation test with 5000 permutations for obtaining P-values for each pathway. In our 
research, we use square root mean as the evidence of gene set, the reason we choose this has been stated in 
previous section. For real data analysis in our research, we produce a self-contained test for GESA method. 
Lai et al. (Lai, et al., 2014) introduce a concordant integrative gene set enrichment analysis method. This 
research focuses on low-sample expression data, and they apply the method on two microarray gene 
expression data sets. They choose traditional two-sample student’s t-test to screen genes. Then, they propose 
a mixture model with three normal distributions which represent three conditions (genes not differentially 
expressed, up-regulated and down-regulated) for each individual gene expression data set. The model is 
estimated by the E-M algorithm. After this, they derive the probability for a gene to be in a pre- defined gene 
set, then calculate the concordant gene set enrichment score by a partial concordance/discordance (PCD) 
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model. For computational convenience, a Monte Carlo approximation is produced. Lastly, a p-value is 
obtained based on the likelihood ratio test. This method is quite different from ours, in that they create a 
mixture modeling statistical method for concordant integrated gene set enrichment analysis. So, before 
integrated analysis they can statistically test for genome-wide concordance. Second, it is convenient for 
calculating the FDR due to using a probabilistic framework for integrated analysis of gene sets. But on the 
other hand, there are several disadvantages. The mixture model is simple due to being restricted to the two-
sample situation. Second, they assume that genes are independent. In our research, we do not need the 
restrictive assumption of independent among genes, and we use SCCA to investigate the correlation trend 
throughout the entire data set.    
There are several advantages for the sparse canonical correlation method. First, it does not consider individual 
pairwise correlations but rather the correlation pattern on a global (genome-wide) scale. Sparse CCA can 
provide the main characteristics of the data by condensing the variables into a smaller dimension. In our case, 
for instance, genes contained in the same pathway may have a similar effect from the variations in multiple 
regulatory elements (e.g., miRNA expression and methylation patterns). Second, the GSEA score contains 
contributions from both mRNA expression and miRNA expression / gene methylation. For integrating 
miRNA and mRNA expression into a GSEA score we create putative target matrix of the miRNAs and then 
combine this with the measurements from the miRNA expression using SCCA. Hence this procedure 
explicitly takes miRNA expression into account in the GSEA score. In previous methods (e.g. MMIA(Nam, 
et al., 2009), mirAct (Liang, et al., 2011), and MAGIA (Sales, et al., 2010)), they generally simply take list 
of up regulated differentially expressed genes intersected with targeting genes of down regulated 
differentially expressed miRNAs. 
Some limitations of our approach include the computational burden associated with calculating the optimal 
penalty for SCCA (Witten and Tibshirani, 2009). In the GSEA test for this research, we first calculated the 
permuted p-value of each gene set using the competitive test. This approach permuted the statistic associated 
with each gene and re-calculated the gene-set scores for each permutation, and had the advantage of being 
computationally fast. However, the competitive test evaluates the null hypothesis that the composite score 
for a given gene set is different from the other gene sets (hence the term competitive). In contrast, the self-
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contained test (which permutes the samples for calculating the null distribution) addresses the null hypothesis 
of more direct biological interest, that the gene set does not contain genes whose expression levels are 
associated with the phenotype of interest. Further, the re-sampling strategy of the competitive test is gene-
based (as opposed to sample-based), which is not in-line with the experimental design and has the underlying 
assumption that the statistics associated with all the genes are independent.  Hence in our real data analysis 
we opted for using the self-contained test to evaluate the alternative that the gene set contains genes that are 
differentially expressed (associated with the phenotype) and also regulated by miRNAs. But since there is an 
additional permutation procedure to obtain the optimal shrinkage penalty in SCCA (e.g., using the 
CCA.permute function), the self-contained test is quite computationally burdensome (i.e. one permutation 
for finding multiple canonical vectors takes 10-20 minutes). So, despite the limitations we used the 
competitive test method for the simulation study. And though we used the self-contained test for real data 
analysis, we used the same shrinkage penalty from the original data set for each permutation.  
In our simulation study involving multiple gene sets, we found that when the sample size increased the 
permuted optimal parameter λ for SCCA might be very restrictive. This means that very few miRNAs and 
mRNAs will have non-zero loadings on the canonical correlation weight vectors. In this case, the power of 
SCCA will start to decrease for larger sample sizes. However, this situation is addressed by using the one 
standard deviation rule to select a larger λ and hence involve more miRNAs and mRNAs. 
Another possible extension to our SCCA-GSEA approach is to directly incorporate covariates. In our current 
research, we first detected down regulated differentially expressed miRNAs and then applied SCCA on these 
DE miRNAs and whole mRNA data sets to calculate canonical weight vectors. But in CCA we can directly 
incorporate a phenotype to identify features that are correlated across the whole miRNA and mRNA data sets 
and also correlated with the phenotype (Witten and Tibshirani, 2009). Then, we could use SCCA on the 
complete miRNA and mRNA data sets coupled with the covariates. The alternative approach allows 
extensions to survival data, multiple class data or quantitative data.   
SCCA often overlooks the structural or group effect within genomic data, which can be important (e.g., 
methylation probes in a MRI interact and work together as a group). In this case, group sparse canonical 
correlation analysis (Lin, et al., 2013) is introduced to analyze the relationship between two different types 
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of genomic data (i.e., methylated probes and gene expression in our research). We did do a preliminary 
application of the group SCCA method (Lin, et al., 2013) on our mRNA expression / gene methylation data. 
We start by obtaining initial canonical weight vectors by applying SCCA on the two data sets. Then, we treat 
each MRI as a group, and use the iterative group sparse CCA algorithm to obtain updated canonical weight 
vectors starting from the initial estimates from SCCA. Next, we create a GSEA score with the new canonical 
vectors based on the group SCCA approach by the same method we described in Chapter V. In future studies, 
we will conduct a simulation study for the group SCCA method and compared it with SCCA for detecting 
enriched gene sets.   
In conclusion, in this research we applied sparse canonical correlation analysis for both integrated analysis 
of mRNA expression / miRNA expression and mRNA expression / gene methylation. We then developed 
two novel gene set enrichment analysis statistics based on these integrated analysis using SCCA, and 
evaluated the performance on both real and simulated data sets. The performance of the proposed statistics 
shows promise for identifying biological pathways enriched for genes regulated by miRNA expression or 
gene methylation. Potential future extensions include using more sophisticated penalty functions and 




Abatangelo, L., et al. Comparative study of gene set enrichment methods. BMC bioinformatics 
2009;10:275-275. 
 
Baylin, S.B. DNA methylation and gene silencing in cancer. Nature clinical practice. Oncology 2005;2 
Suppl 1:S4-11. 
 
Benjamini, Y. and Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach 
to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological) 1995;57(1):289-
300. 
 
Bird, A. DNA methylation patterns and epigenetic memory. 2002(0890-9369 (Print)). 
 
Corney, D.C., et al. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell  
proliferation and adhesion-independent growth. Cancer research 2007;67(18):8433-8438. 
 
Efron, B. and Tibshirani, R. On testing the significance of sets of genes. 2007:107-129. 
 
Ferretti, E., et al. MicroRNA profiling in human medulloblastoma. International journal of cancer. Journal 
international du cancer 2009;124(3):568-577. 
 
Flynt, A.S. and Lai, E.C. Biological principles of microRNA-mediated regulation: shared themes amid 
diversity. Nature reviews. Genetics 2008;9(11):831-842. 
 
Gifi, A. Nonlinear Multivariate Analysis. Wiley; 1990. 
 
Gonzalo, S. Epigenetic alterations in aging. Journal of applied physiology (Bethesda, Md. : 1985) 
2010;109(2):586-597. 
 
Gottardo, F., et al. Micro-RNA profiling in kidney and bladder cancers. Urologic Oncology: Seminars and 
Original Investigations 2007;25(5):387-392. 
 
Haines, T.R., Rodenhiser, D.I. and Ainsworth, P.J. Allele-specific non-CpG methylation of the Nf1 gene 
during early mouse development. Developmental biology 2001;240(2):585-598. 
 
Herman, J.G. and Baylin, S.B. Gene silencing in cancer in association with promoter hypermethylation. 
The New England journal of medicine 2003;349(21):2042-2054. 
 
Hotelling, H. Relations Between Two Sets of Variates. Biometrika 1936;28:321. 
 
Jiang, Z. and Gentleman, R. Extensions to gene set enrichment. Bioinformatics (Oxford, England) 
2007;23(3):306-313. 
 
John, B., et al. Human MicroRNA Targets. PLoS Biol 2004;2(11):e363.
 





Kanehisa, M., et al. The KEGG resource for deciphering the genome. Nucleic Acids Research 
2004;32(Database issue):D277-D280. 
 
Kozomara, A. and Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep 
sequencing data. Nucleic Acids Research 2014;42(Database issue):D68-D73. 
 
Kren, B.T., et al. microRNAs identified in highly purified liver-derived mitochondria may play a role in 
apoptosis. RNA biology 2009;6(1):65-72. 
 
Lai, Y., et al. Concordant integrative gene set enrichment analysis of multiple large-scale two-sample 
expression data sets. BMC Genomics 2014;15(Suppl 1):S6. 
 
Lakshmipathy, U., et al. Micro RNA expression pattern of undifferentiated and differentiated human 
embryonic stem cells. Stem cells and development 2007;16(6):1003-1016. 
 
Lewis, B.P., et al. Prediction of Mammalian MicroRNA Targets. Cell 2003;115(7):787-798. 
 
Liang, Z., et al. mirAct: a web tool for evaluating microRNA activity based on gene expression data. 
Nucleic Acids Research 2011;39(Web Server issue):W139-W144. 
 
Lin, D., et al. Group sparse canonical correlation analysis for genomic data integration. BMC 
bioinformatics 2013;14(1):1-16. 
 
Lister, R., et al. Global Epigenomic Reconfiguration During Mammalian Brain Development. Science 
(New York, N.Y.) 2013;341(6146). 
 
Lister, R., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. 
Nature 2009;462(7271):315-322. 
 
Lu, J., et al. MicroRNA expression profiles classify human cancers. Nature 2005;435(7043):834-838. 
 
Nam, S., et al. MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological 
functions of microRNA expression. Nucleic Acids Research 2009;37(Web Server issue):W356-W362. 
 
Nelson, K.M. and Weiss, G.J. MicroRNAs and cancer: past, present, and potential future. Molecular cancer 
therapeutics 2008;7(12):3655-3660. 
 
Nilsen, T.W. Mechanisms of microRNA-mediated gene regulation in animal cells. Trends in genetics : TIG 
2007;23(5):243-249. 
 
Parkhomenko, E., Tritchler, D. and Beyene, J. Sparse Canonical Correlation Analysis with Application to 
Genomic Data Integration. In, Statistical Applications in Genetics and Molecular Biology. 2009. p. 1. 
 
Poisson, L.M., Taylor, J.M. and Ghosh, D. Integrative set enrichment testing for multiple omics platforms. 
BMC bioinformatics 2011;12(1):1-11. 
 
Ritchie, M.E., et al. limma powers differential expression analyses for RNA-sequencing and microarray 
studies. Nucleic Acids Res 2015. 
 
Sales, G., et al. MAGIA, a web-based tool for miRNA and Genes Integrated Analysis. Nucleic Acids 
Research 2010;38(Web Server issue):W352-W359. 
 





Seelan, R.S., et al. Developmental profiles of the murine palatal methylome. Birth defects research. Part A, 
Clinical and molecular teratology 2013;97(4):171-186. 
 
Smyth, G.K. Linear Models and Empirical Bayes Methods for Assessing Differential Expression in 
Microarray Experiments. In, Statistical Applications in Genetics and Molecular Biology. 2004. p. 1. 
 
Subramanian, A., et al. Gene set enrichment analysis: A knowledge-based approach for interpreting 
genome-wide expression profiles. Proceedings of the National Academy of Sciences 2005;102(43):15545-
15550. 
 
Tatsuguchi, M., et al. Expression of microRNAs is dynamically regulated during cardiomyocyte 
hypertrophy. Journal of molecular and cellular cardiology 2007;42(6):1137-1141. 
 
Tian, L., et al. Discovering statistically significant pathways in expression profiling studies. Proceedings of 
the National Academy of Sciences of the United States of America 2005;102(38):13544-13549. 
 
Tibshirani, R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society. 
Series B (Methodological) 1996:267-288. 
 
Tibshirani, R., et al. Sparsity and smoothness via the fused lasso. Journal of the Royal Statistical Society: 
Series B (Statistical Methodology) 2005;67(1):91-108. 
 
Ting, A.H., et al. Short double-stranded RNA induces transcriptional gene silencing in human cancer cells 
in the absence of DNA methylation. Nature genetics 2005;37(8):906-910. 
 
Toedling, J., et al. Ringo--an R/Bioconductor package for analyzing ChIP-chip readouts. BMC 
bioinformatics 2007;8:221. 
 
Tucker, K.L. Methylated cytosine and the brain: a new base for neuroscience. Neuron 2001;30(3):649-652. 
 
Witten, D.M., Tibshirani, R. and Hastie, T. A penalized matrix decomposition, with applications to sparse 
principal components and canonical correlation analysis. Biostatistics 2009;10(3):515-534. 
 
Witten, D.M. and Tibshirani, R.J. Extensions of Sparse Canonical Correlation Analysis with Applications 
to Genomic Data. Statistical Applications in Genetics and Molecular Biology 2009;8(1):Article 28. 
 
Wossidlo, M., et al. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic 
reprogramming. Nature communications 2011;2:241. 
 
Zhan, M., et al. MicroRNA expression dynamics during murine and human erythroid differentiation. 







 Department of Biostatistics & Bioinformatics                                            Phone: (502) 432-2129                 
 University of Louisville                                                               Email:d0yang03@Louisville.edu 
 School of Public Health and Information Sciences 
 485 E. Gray St, Louisville, KY  40202 
 
EDUCATION 
 Ph.D. in Biostatistics                                                                              Sep. 2011 - present 
      Department of Biostatistics & Bioinformatics, University of Louisville 
      Advisor: Guy Brock, Ph.D 
 M.S. in Biostatistics                                                                                Sep. 2009 - May 2011 
      Department of Biostatistics & Bioinformatics, University of Louisville 
      Advisor: Guy Brock, Ph.D 
 B.S. in Statistics                                                                                      Sep. 2004 - May 2008 
Department of Mathematics, Beijing Institute of Technology, P. R. China. 
 
RESEARCH INTERESTS 
 Integrated analysis of miRNA-mRNA data and mRNA-methylation data
115 
 
 Empirical evaluation of methods to detect differentially expressed genes 




1. Yang, D., Parrish, R. S., & Brock, G. N. (2014). Empirical Evaluation of Consistency and Accuracy 
of Methods to Detect Differentially Expressed Genes Based on Microarray Data. Computers in 
Biology and Medicine, 46, 1–10. (Honorable Mention Paper (Top 10%), Computers in Biology and 
Medicine, 2014) 
2. Li, M., Yang, D., Brock, G. N., Knipp, R. J., Bousamra, M., Nantz, M.H., and Fu, X. A. (2015). 
Breath Carbonyl Compounds as Biomarkers of Lung Cancer. Accepted to Lung Cancer. 
3. Alton, T., Brock, G. N., Yang, D., Wilkings, D. A., Hertweck, S. P., Loveless, M. B. (2012). 
Retrospective Review of Intrauterine Device in Adolescent and Young Women. Journal of Pediatric 
and Adolescent Gynecology, 25(3), 195-200.  
 
In progress 
 Yang, D., Mukhopadhyay, P., Greene, R. M., Pisano, M. M., and Brock, G.N. (2015+). 
Integrated Analysis of miRNA-mRNA Expression profiles using Sparse Canonical Correlation Analysis.  
(planned submission to BMC Bioinformatics). 
 Mukhopadhyay, P., Brock, G., Yang, D., Greene, Robert. M., and Pisano, M. M. (2015+). 
Developmental gene expression profiling of mammalian, embryonic neural tube. (planned submission 





 Poster presentations 
 “Integrated analysis of miRNA-mRNA expression profiles,” at Joint Statistical Meetings, 
Seattle, Washington. (August 2015, scheduled) 
 “Integrated analysis of miRNA-mRNA expression profiles,” at UT-KBRIN Bioinformatics 
summit, Buchanan, Tennessee. (March 2015) 
 “Consistency of Differentially Expressed Gene Rankings Based on Subsets of Microarray Data,” 
at UT-ORNL-KBRIN Bioinformatics Summit, Memphis, Tennessee. (March 2011) 
 
RESEARCH EXPERIENCE 
 Graduate Research Assistant                                                                     Sep 2011- present 
Department of Biostatistics & Bioinformatics, University of Louisville 
 
Methodological Research 
 Develop methods for integrated analysis of miRNA- mRNA expression profiles. MicroRNAs 
(miRNAs) are a large number of small endogenous non-coding RNA molecules (18-25 
nucleotides in length) which regulate expression of genes post-transcriptionally. While a variety 
of algorithms exist for determining the targets of miRNAs, they are generally based on sequence 
information and frequently produce lists consisting of thousands of genes. Canonical 
correlation analysis (CCA) is a multivariate statistical method that can be used to find linear 
relationships between two data sets, and here we apply CCA to find the linear combination of 
differentially expressed miRNAs and their corresponding target genes having maximal negative 
correlation.  Due to the high dimensionality, sparse CCA is used to constrain the problem and 
obtain a solution.  A novel gene set enrichment analysis statistic is proposed based on the sparse 
117 
 
CCA results for estimating the significance of predefined gene sets. The methods are illustrated 
with both a simulation study and real miRNA-mRNA expression data concerning the murine 
embryonic developing neural tube, and also other cancer data sets. 
  
Collaborative Research 
 Statistical support for the project “Confirmation of a VOC profile characteristic of lung cancer 
from exhaled human breath using chemoselective silicon microreactors,” (PI: Dr. Xiaoan Fu, 
J.B., Speed School of Engineering, University of Louisville), including developing 
classification models to assess the relationship between VOC markers and lung cancer cases / 
controls, and making ROC plots. 
 Statistical support for Dr. Emma M. Sterrett (Family Therapy Program Kent School of Social 
Work, University of Louisville) to assess the relationship between various types of adolescent 
support and delinquency / drinking age.  
 Statistical support for the project “Effects of Educational Intervention on Long-Term Outcomes 
of Hospitalized Children with Asthma,” (PI: Dr. Tania Condurache, Department of Pediatrics, 
University of Louisville School of Medicine), including testing for differences between the 
control and intervention groups on frequency of hospital visits, number of missed school days, 
etc. 
 Statistical support for the project “Predicting Percent Weight Loss in BARIA Surgical Patients 
Using EGG 7 Weeks Following Surgery” (PI: Dr. Thomas L. Abell., Department of Medicine, 
Gastroenterology, Hepatology and Nutrition, University of Louisville) including analyzing the 
BARIA study data to develop a multivariable model to predict the percent weight loss for 






 Statistical software: proficient in R, SAS. 
 Applications: proficient in MS Office and LaTeX. 
 
HONORS AND AWARDS 
 University Fellowship at University of Louisville.                                                  2011 - 2013 
 Outstanding Student Award, Beijing Institute of Technology, P. R. China.            2005 - 2008 
 
REFERENCES 
 Guy Brock, Ph.D. 
Associate Professor, Department of Bioinformatics and Biostatistics, University of Louisville.   
guy.brock@louisville.edu, (502) 852-3444. 
 
 KB Kulasekera, Ph.D. 
Chair and Professor, Department of Bioinformatics and Biostatistics, University of Louisville.   
kb.kulasekera@louisville.edu, (502) 852-6422. 
 
 Maiying Kong, Ph.D. 
Associate Professor, Department of Bioinformatics and Biostatistics, University of Louisville.   
maiying.kong@louisville.edu, (502) 852-3988. 
119 
 
 Dongfeng Wu, Ph.D. 
Associate Professor, Department of Bioinformatics and Biostatistics, University of Louisville.   
dongfeng.wu@louisville.edu, (502) 852-1888
 
